{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:10:51Z","timestamp":1794438651425,"version":"4.9.1"},"reference-count":438,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR)\u2013engineered cell therapies represent a significant breakthrough in immunotherapy, initially in cancer and now expanding into diverse clinical fields. While originally developed for oncology, these platforms are increasingly being adapted for non-malignant conditions such as autoimmune disorders, infectious diseases, fibrosis, ageing-related issues, and organ transplants. This review details the evolution and diversification of CAR modalities- including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells- as well as emerging next-generation designs. It describes the key aspects of CAR structure, signalling pathways, and manufacturing, emphasising their application in treating hematologic and solid tumours, while considering challenges such as the tumour microenvironment (TME). The review also discusses expanding uses beyond cancer- such as CD19\/BCMA-targeted CAR-T cells achieving long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression, CAR-NK approaches targeting HIV, CAR-Tregs enhancing transplant tolerance, and senolytic CARs reducing tissue fibrosis. Up-to-date research through 2025 is summarised to evaluate efficacy, safety, and adverse events, noting that CAR therapies show lower cytokine release syndrome (CRS) in autoimmune diseases. Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted, alongside ongoing challenges such as manufacturing complexity, high costs, and antigen escape. Trials like KYV-101 for multiple sclerosis demonstrate continued progress and the potential of these therapies to translate into clinical practice. Overall, CAR-engineered treatments enable precise, programmable immune modulation, paving the way for advanced therapies across an expanding array of diseases.<\/jats:p>","DOI":"10.1186\/s43556-025-00401-4","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:43:00Z","timestamp":1768963380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["CAR-engineered cell therapies: current understandings and future perspectives"],"prefix":"10.1186","volume":"7","author":[{"given":"Mobina","family":"Bayat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-6869","authenticated-orcid":false,"given":"Javid Sadri","family":"Nahand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"1","key":"401_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41419-024-06438-7","volume":"15","author":"B Zhang","year":"2024","unstructured":"Zhang B, Yang M, Zhang W, Liu N, Wang D, Jing L, et al. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside. Cell Death Dis. 2024;15(1):50. https:\/\/doi.org\/10.1038\/s41419-024-06438-7.","journal-title":"Cell Death Dis"},{"issue":"4","key":"401_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","volume":"17","author":"DA Boardman","year":"2017","unstructured":"Boardman DA, Philippeos C, Fruhwirth GO, Ibrahim MA, Hannen RF, Cooper D, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transplant. 2017;17(4):931\u201343.","journal-title":"Am J Transplant"},{"issue":"7","key":"401_CR3","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/eji.200940278","volume":"41","author":"C Kuylenstierna","year":"2011","unstructured":"Kuylenstierna C, Bj\u00f6rkstr\u00f6m NK, Andersson SK, Sahlstr\u00f6m P, Bosnjak L, Paquin-Proulx D, et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol. 2011;41(7):1913\u201323.","journal-title":"Eur J Immunol"},{"issue":"9","key":"401_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41423-021-00732-6","volume":"18","author":"C Zhang","year":"2021","unstructured":"Zhang C, Hu Y, Xiao W, Tian Z. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol. 2021;18(9):2083\u2013100. https:\/\/doi.org\/10.1038\/s41423-021-00732-6.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"401_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02081-0","volume":"23","author":"M Bayat","year":"2024","unstructured":"Bayat M, Sadri Nahand J. Exosomal miRNAs: the tumor\u2019s trojan horse in selective metastasis. Mol Cancer. 2024;23(1):167. https:\/\/doi.org\/10.1186\/s12943-024-02081-0.","journal-title":"Mol Cancer"},{"issue":"6","key":"401_CR6","volume":"1879","author":"S Mohamadi","year":"2024","unstructured":"Mohamadi S, Mehrasa P, Mehramuz B, Kobravi S, Taghizadieh M, Salmaninejad A, et al. The tumor microenvironment\u2019s gambit: exosomal pawns on the board of head and neck cancer. Biochimica et Biophysica Acta (BBA). 2024;1879(6):189189.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"401_CR7","doi-asserted-by":"crossref","unstructured":"Bayat M, Nahand JS. Battlegrounds of treatment resistance: decoding the tumor microenvironment. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:11179\u201311197.","DOI":"10.1007\/s00210-025-04055-5"},{"issue":"5","key":"401_CR8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085\u201395. https:\/\/doi.org\/10.1038\/s41423-021-00655-2.","journal-title":"Cell Mol Immunol"},{"issue":"57","key":"401_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd4344","volume":"6","author":"M Boulch","year":"2021","unstructured":"Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lema\u00eetre F, et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021;6(57):eabd4344. https:\/\/doi.org\/10.1126\/sciimmunol.abd4344.","journal-title":"Sci Immunol"},{"key":"401_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther. 2022;25:69\u201377. https:\/\/doi.org\/10.1016\/j.omto.2022.03.009.","journal-title":"Mol Ther"},{"key":"401_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","volume":"470","author":"X Lei","year":"2020","unstructured":"Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126\u201333.","journal-title":"Cancer Lett"},{"issue":"6230","key":"401_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380.","journal-title":"Science"},{"key":"401_CR13","doi-asserted-by":"publisher","unstructured":"Segovia MF, Landoni D, Defranchi Y, Jofr\u00e9 RC, Olivares CF, Keppeke G. A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes\u2014a brief review. Exploration Immunol. 2025. https:\/\/doi.org\/10.37349\/ei.2025.1003185.","DOI":"10.37349\/ei.2025.1003185"},{"key":"401_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583:127\u201332. https:\/\/doi.org\/10.1038\/s41586-020-2403-9.","journal-title":"Nature"},{"key":"401_CR15","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano V, Wada M, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83:1304\u201314. https:\/\/doi.org\/10.1136\/ard-2024-225785.","journal-title":"Ann Rheum Dis"},{"key":"401_CR16","doi-asserted-by":"publisher","unstructured":"Mao Y, Yao C, Zhang SQ, Zeng Q, Wang J, Sheng C, et al. Targeting fibroblast activation protein with chimeric antigen receptor macrophages. Biochem Pharmacol. 2024:116604. https:\/\/doi.org\/10.1016\/j.bcp.2024.116604.","DOI":"10.1016\/j.bcp.2024.116604"},{"key":"401_CR17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186669","author":"J Feng","year":"2023","unstructured":"Feng J, Hu YX, Chang A, Huang H. CD19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus - safety and preliminary efficacy data from a phase I clinical study. Blood. 2023. https:\/\/doi.org\/10.1182\/blood-2023-186669.","journal-title":"Blood"},{"issue":"10416","key":"401_CR18","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/s0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416):2034\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(23)01126-1.","journal-title":"Lancet"},{"key":"401_CR19","doi-asserted-by":"publisher","unstructured":"Nie W, Yang X, Mingrui, Xu X, Hou J. Chimeric antigen receptor T cell therapy for autoimmune diseases. Curr Opin Immunol. 2025;95:102596. https:\/\/doi.org\/10.1016\/j.coi.2025.102596.","DOI":"10.1016\/j.coi.2025.102596"},{"key":"401_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.01.002","author":"MH Lin","year":"2025","unstructured":"Lin MH, Hu LJ, Miller J, Huang X, Zhao XY. CAR-NK cell therapy: a potential antiviral platform. Sci Bull. 2025. https:\/\/doi.org\/10.1016\/j.scib.2025.01.002.","journal-title":"Sci Bull"},{"key":"401_CR21","doi-asserted-by":"publisher","unstructured":"Bauser M, Einsele H, L\u00f6ffler J, Hudecek M, Seif M. Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System. J Vis Exp. 2024;212. https:\/\/doi.org\/10.3791\/67424.","DOI":"10.3791\/67424"},{"key":"401_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jleuko\/qiac007","volume":"113","author":"R Anderko","year":"2023","unstructured":"Anderko R, Mailliard R. Mapping the interplay between NK cells and HIV: therapeutic implications. J Leukoc Biol. 2023;113:109\u201338. https:\/\/doi.org\/10.1093\/jleuko\/qiac007.","journal-title":"J Leukoc Biol"},{"key":"401_CR23","doi-asserted-by":"publisher","unstructured":"Duan S, Liu S. Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.842746.","DOI":"10.3389\/fimmu.2022.842746"},{"key":"401_CR24","doi-asserted-by":"publisher","unstructured":"Reis FD, Saidani Y, Mart\u00edn-Rubio P, Sanz-Pamplona R, Stojanovic A, Correia M. CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1603757.","DOI":"10.3389\/fimmu.2025.1603757"},{"key":"401_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/itt.s291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda R, Dimou P, D\u2019Souza R, Klampatsa A. Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma. Immunotargets Ther. 2021;10:313\u201323. https:\/\/doi.org\/10.2147\/itt.s291767.","journal-title":"Immunotargets Ther"},{"key":"401_CR26","doi-asserted-by":"publisher","unstructured":"Yashaswini C, Cogliati B, Qin T, To T, Williamson T, Papp T, et al. In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.02.25.640143.","DOI":"10.1101\/2025.02.25.640143"},{"key":"401_CR27","doi-asserted-by":"publisher","unstructured":"Chan AML, Sakthiswary R, Lokanathan Y. Revolutionizing Allogeneic Graft Tolerance Through Chimeric Antigen Receptor-T Regulatory Cells. Biomedicines. 2025;13. https:\/\/doi.org\/10.3390\/biomedicines13071757.","DOI":"10.3390\/biomedicines13071757"},{"key":"401_CR28","doi-asserted-by":"publisher","unstructured":"Rui X, Calderon FA, Wobma H, Gerdemann U, Albanese A, Cagnin L, et al. Human OX40L\u2013CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity. Sci Transl Med. 2024;16. https:\/\/doi.org\/10.1126\/scitranslmed.adj9331.","DOI":"10.1126\/scitranslmed.adj9331"},{"key":"401_CR29","doi-asserted-by":"publisher","unstructured":"Wagner J, Tang Q. CAR-Tregs as a Strategy for Inducing Graft Tolerance. Curr Transplant Rep. 2020:1\u201310. https:\/\/doi.org\/10.1007\/s40472-020-00285-z.","DOI":"10.1007\/s40472-020-00285-z"},{"issue":"4","key":"401_CR30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1172\/jci86827","volume":"126","author":"M Edinger","year":"2016","unstructured":"Edinger M. Driving allotolerance: CAR-expressing Tregs for tolerance induction in organ and stem cell transplantation. J Clin Invest. 2016;126(4):1248\u201350. https:\/\/doi.org\/10.1172\/jci86827.","journal-title":"J Clin Invest"},{"key":"401_CR31","doi-asserted-by":"publisher","unstructured":"Gille I, Claas F, Haasnoot G, Heemskerk M, Heidt S. Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.874157.","DOI":"10.3389\/fimmu.2022.874157"},{"key":"401_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107352","volume":"208","author":"B Spokeviciute","year":"2024","unstructured":"Spokeviciute B, Kholia S, Brizzi MF. Chimeric antigen receptor (CAR) T-cell therapy: harnessing extracellular vesicles for enhanced efficacy. Pharmacol Res. 2024;208:107352.","journal-title":"Pharmacol Res"},{"issue":"6","key":"401_CR33","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"401_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01965","volume":"11","author":"MA Morgan","year":"2020","unstructured":"Morgan MA, B\u00fcning H, Sauer M, Schambach A. Use of cell and genome modification technologies to generate improved \u201coff-the-shelf\u201d CAR T and CAR NK cells. Front Immunol. 2020;11:1965.","journal-title":"Front Immunol"},{"issue":"1","key":"401_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2024;25(1):102\u201316.","journal-title":"Nat Immunol"},{"issue":"1","key":"401_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13(1):76.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"401_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23(1):86.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"401_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"1","key":"401_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21(1):47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"401_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71\u201384. https:\/\/doi.org\/10.1038\/s41571-020-0427-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7655","key":"401_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain M, Rivi\u00e8re I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545(7655):423\u201331.","journal-title":"Nature"},{"key":"401_CR42","first-page":"92","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther. 2017;4:92\u2013101.","journal-title":"Mol Ther"},{"key":"401_CR43","doi-asserted-by":"publisher","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015,\u00a01\u20137. https:\/\/doi.org\/10.1038\/mto.2016.15.","DOI":"10.1038\/mto.2016.15"},{"issue":"4","key":"401_CR44","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724\u201340.","journal-title":"Cell"},{"issue":"16","key":"401_CR45","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RP, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u201313.","journal-title":"J Clin Oncol"},{"issue":"2","key":"401_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","volume":"26","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26(2):111\u20137.","journal-title":"Trends Immunol"},{"issue":"7","key":"401_CR47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907\u201312.","journal-title":"J Exp Med"},{"issue":"6","key":"401_CR48","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210\u201321.","journal-title":"J Clin Invest"},{"issue":"19","key":"401_CR49","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"401_CR50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"BY Wang","year":"2019","unstructured":"Wang BY, Zhao WH, Liu J, Chen YX, Cao XM, Yang Y, et al. Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). Blood. 2019;134:579.","journal-title":"Blood"},{"issue":"1","key":"401_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.","journal-title":"J Hematol Oncol"},{"key":"401_CR52","volume-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial","author":"S Mailankody","year":"2018","unstructured":"Mailankody S, Ghosh A, Staehr M, Purdon TJ, Roshal M, Halton E, et al. Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial. DC: American Society of Hematology Washington; 2018."},{"key":"401_CR53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131515","volume":"134","author":"AL Garfall","year":"2019","unstructured":"Garfall AL, Cohen AD, Lacey SF, Tian L, Hwang WT, Vogl DT, et al. Combination anti-Bcma and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma. Blood. 2019;134:1863.","journal-title":"Blood"},{"issue":"8","key":"401_CR54","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494\u2013502.","journal-title":"Trends Immunol"},{"key":"401_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"1","key":"401_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"401_CR57","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/jco.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20\u20132. https:\/\/doi.org\/10.1200\/jco.2006.05.9964.","journal-title":"J Clin Oncol"},{"issue":"4","key":"401_CR58","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"issue":"7","key":"401_CR59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89172","volume":"17","author":"H Shamim","year":"2025","unstructured":"Shamim H, Jhakri K, Al-Shudifat M, Sumra B, Kocherry C, Malasevskaia I. Chimeric Antigen Receptor T-cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Efficacy, Safety, and Future Directions. Cureus. 2025;17(7):e89172. https:\/\/doi.org\/10.7759\/cureus.89172.","journal-title":"Cureus"},{"issue":"1","key":"401_CR60","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2024.010","volume":"16","author":"U Testa","year":"2024","unstructured":"Testa U, Sica S, Pelosi E, Castelli G, Leone G. CAR-T cell therapy in B-cell acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2024;16(1):e2024010. https:\/\/doi.org\/10.4084\/mjhid.2024.010.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"10","key":"401_CR61","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jtct.2023.07.016","volume":"29","author":"RM Myers","year":"2023","unstructured":"Myers RM, Jacoby E, Pulsipher MA, Pasquini MC, Grupp SA, Shah NN, et al. Inspired symposium part 1: clinical variables associated with improved outcomes for children and young adults treated with chimeric antigen receptor T cells for B cell acute lymphoblastic leukemia. Transplant Cell Ther. 2023;29(10):598\u2013607. https:\/\/doi.org\/10.1016\/j.jtct.2023.07.016.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"401_CR62","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1200\/jco.23.01314","volume":"42","author":"C Rossig","year":"2024","unstructured":"Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, et al. Chimeric antigen receptor (CAR) T-cell products for pediatric cancers: why alternative development paths are needed. J Clin Oncol. 2024;42(3):253\u20137. https:\/\/doi.org\/10.1200\/jco.23.01314.","journal-title":"J Clin Oncol"},{"issue":"4","key":"401_CR63","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"401_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"401_CR65","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"6","key":"401_CR66","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJ, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"401_CR67","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/j.bbmt.2018.12.311","volume":"25","author":"A Schaefer","year":"2019","unstructured":"Schaefer A, Saygin C, Maakaron J, Hoelscher T, Purdin Z, Robinson J, et al. Cytopenias after chimeric antigen receptor T-cells (CAR-T) infusion; patterns and outcomes. Biol Blood Marrow Transplant. 2019;25(3):S171.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"401_CR68","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u201319.","journal-title":"Cancer Discov"},{"issue":"7","key":"401_CR69","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","volume":"41","author":"H Shalabi","year":"2018","unstructured":"Shalabi H, Wolters PL, Martin S, Toledo-Tamula MA, Roderick MC, Struemph K, et al. Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. J Immunother. 2018;41(7):350\u20138.","journal-title":"J Immunother"},{"key":"401_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.","journal-title":"Front Pharmacol"},{"key":"401_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00254","volume":"5","author":"BS Jones","year":"2014","unstructured":"Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254.","journal-title":"Front Pharmacol"},{"issue":"21","key":"401_CR72","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1182\/blood.V120.21.949.949","volume":"120","author":"M Casucci","year":"2012","unstructured":"Casucci M, di Robilant BN, Falcone L, Camisa B, Genovese P, Gentner B, et al. Co-expression of a suicide gene in CAR-redirected T cells enables the safe targeting of CD44v6 for leukemia and myeloma eradication. Blood. 2012;120(21):949.","journal-title":"Blood"},{"key":"401_CR73","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2018.00507","volume":"9","author":"M Casucci","year":"2018","unstructured":"Casucci M, Falcone L, Camisa B, Norelli M, Porcellini S, Stornaiuolo A, et al. Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene. Front Immunol. 2018;9:507.","journal-title":"Front Immunol"},{"issue":"18","key":"401_CR74","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383.","journal-title":"N Engl J Med"},{"key":"401_CR75","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2019-126660","volume":"134","author":"JG Berdeja","year":"2019","unstructured":"Berdeja JG, Alsina M, Shah ND, Siegel DS, Jagannath S, Madduri D, et al. Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy. Blood. 2019;134:927.","journal-title":"Blood"},{"key":"401_CR76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121731","volume":"134","author":"D Madduri","year":"2019","unstructured":"Madduri D, Usmani SZ, Jagannath S, Singh I, Zudaire E, Yeh TM, et al. Results from CARTITUDE-1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM). Blood. 2019;134:577.","journal-title":"Blood"},{"key":"401_CR77","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1182\/blood-2019-127309","volume":"134","author":"E Zudaire","year":"2019","unstructured":"Zudaire E, Madduri D, Usmani SZ, Jakubowiak A, Berdeja JG, Geng D, et al. Translational analysis from CARTITUDE-1, an ongoing phase 1b\/2 study of JNJ-4528 BCMA-targeted CAR-T cell therapy in relapsed and\/or refractory multiple myeloma (R\/R MM), indicates preferential expansion of CD8+ T cell central memory cell subset. Blood. 2019;134:928.","journal-title":"Blood"},{"issue":"4","key":"401_CR78","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2217\/rme-2020-0009","volume":"15","author":"D Ilic","year":"2020","unstructured":"Ilic D, Liovic M. Industry updates from the field of stem cell research and regenerative medicine in December 2019. Regen Med. 2020;15(4):1499\u2013507.","journal-title":"Regen Med"},{"key":"401_CR79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117729","volume-title":"Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","author":"DJ Green","year":"2018","unstructured":"Green DJ, Pont M, Sather BD, Cowan AJ, Turtle CJ, Till BG, et al. Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. DC: American Society of Hematology Washington; 2018."},{"key":"401_CR80","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood-2019-129088","volume":"134","author":"L Mikkilineni","year":"2019","unstructured":"Mikkilineni L, Manasanch EE, Lam N, Vanasse D, Brudno JN, Maric I, et al. T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma. Blood. 2019;134:3230.","journal-title":"Blood"},{"key":"401_CR81","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1182\/blood-2019-129405","volume":"134","author":"AJ Cowan","year":"2019","unstructured":"Cowan AJ, Pont M, Sather BD, Turtle CJ, Till BG, Nagengast AM, et al. Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:204.","journal-title":"Blood"},{"key":"401_CR82","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood-2019-129582","volume":"134","author":"DJ Green","year":"2019","unstructured":"Green DJ, Pont M, Cowan AJ, Cole GO, Sather BD, Nagengast AM, et al. Response to Bcma CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase. Blood. 2019;134:1856.","journal-title":"Blood"},{"issue":"8","key":"401_CR83","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"15","key":"401_CR84","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.2174\/0113892010265228231116073012","volume":"25","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li YR. Harnessing chimeric antigen receptor-engineered invariant natural killer T cells: therapeutic strategies for cancer and the tumor microenvironment. Curr Pharm Biotechnol. 2024;25(15):2001\u201311.","journal-title":"Curr Pharm Biotechnol"},{"issue":"4","key":"401_CR85","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JS, Van Deerlin VM, Morrissette JJ, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30(4):984\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"401_CR86","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","volume":"31","author":"R Dulery","year":"2025","unstructured":"Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S, et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. Nat Med. 2025;31(4):1130\u20133.","journal-title":"Nat Med"},{"key":"401_CR87","unstructured":"staff CRC. FDA Approvals in Oncology: July-September 2024. In: American Association for Cancer Research. 2024. https:\/\/www.aacr.org\/blog\/2024\/10\/03\/fda-approvals-in-oncology-july-september-2024\/#:~:text=New%20to%20the%20Market%3A%20Cells,and%20a%20Tumor%2Dseeking%20Toxin&text=Like%20chimeric%20antigen%20receptor%20(CAR,into%20patients%20to%20fight%20cancer. Accessed 3.10.2024 2024."},{"issue":"1","key":"401_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, Chyra Z, Kotulov\u00e1 J, Celichowski P, Mih\u00e1lyov\u00e1 J, Charv\u00e1tov\u00e1 S, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14(1):213.","journal-title":"Blood Cancer J"},{"key":"401_CR89","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.03.012","volume":"178","author":"JE Jaspers","year":"2017","unstructured":"Jaspers JE, Brentjens RJ. Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther. 2017;178:83\u201391. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.03.012.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"401_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7375","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy. Cancer Med. 2024;13(11):e7375.","journal-title":"Cancer Med"},{"issue":"2","key":"401_CR91","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10620-020-06183-9","volume":"66","author":"J Wu","year":"2021","unstructured":"Wu J, Cai J. Dilemma and challenge of immunotherapy for pancreatic cancer. Dig Dis Sci. 2021;66(2):359\u201368.","journal-title":"Dig Dis Sci"},{"key":"401_CR92","doi-asserted-by":"publisher","unstructured":"Abken, H. CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges. Nat Rev Gastroenterol Hepatol. 2025;22:463\u201380. https:\/\/doi.org\/10.1038\/s41575-025-01062-y.","DOI":"10.1038\/s41575-025-01062-y"},{"issue":"2","key":"401_CR93","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet C, Larghero J, Mebarki M. Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv. 2024;8(2):337\u201342.","journal-title":"Blood Adv"},{"key":"401_CR94","doi-asserted-by":"publisher","unstructured":"Aparicio C, Acebal C, Gonz\u00e1lez-Vallinas M. Current approaches to develop \u201coff-the-shelf\u201d chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review. Exp Hematol Oncol. 2023;12. https:\/\/doi.org\/10.1186\/s40164-023-00435-w.","DOI":"10.1186\/s40164-023-00435-w"},{"issue":"5","key":"401_CR95","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.bcd-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman S, Fesnak A, Heslop H, Marks P, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2(5):408\u201322. https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0084.","journal-title":"Blood Cancer Discov"},{"key":"401_CR96","doi-asserted-by":"publisher","unstructured":"Giorgioni L, Ambrosone A, Cometa M, Salvati AL, Nistic\u00f2 R, Magrelli A. Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms251910365.","DOI":"10.3390\/ijms251910365"},{"key":"401_CR97","doi-asserted-by":"publisher","unstructured":"Alidadi M, Barzgar H, Zaman M, Paevskaya O, Metanat Y, Khodabandehloo E, et al. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Front Cell Dev Biol. 2024;12. https:\/\/doi.org\/10.3389\/fcell.2024.1491282.","DOI":"10.3389\/fcell.2024.1491282"},{"key":"401_CR98","doi-asserted-by":"publisher","unstructured":"Razeghian E, Nasution M, Rahman H, Gardanova Z, Kamal W, Aravindhan S, et al. A deep insight into CRISPR\/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem Cell Res Ther. 2021;12. https:\/\/doi.org\/10.1186\/s13287-021-02510-7.","DOI":"10.1186\/s13287-021-02510-7"},{"key":"401_CR99","doi-asserted-by":"publisher","unstructured":"Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M, et al. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J Transl Med. 2025;23. https:\/\/doi.org\/10.1186\/s12967-024-06052-3.","DOI":"10.1186\/s12967-024-06052-3"},{"key":"401_CR100","doi-asserted-by":"publisher","unstructured":"Dias J, Garcia J, Agliardi G, Roddie C. CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development. Mol Ther Methods Clin Dev. 2024;32. https:\/\/doi.org\/10.1016\/j.omtm.2024.101250.","DOI":"10.1016\/j.omtm.2024.101250"},{"issue":"36","key":"401_CR101","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1080\/14796694.2024.2393566","volume":"20","author":"A Sureda","year":"2024","unstructured":"Sureda A, Adam SE, Yang S, Griffin E, Baker J, Johnston K, et al. Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals. Future Oncol. 2024;20(36):2855\u201368. https:\/\/doi.org\/10.1080\/14796694.2024.2393566.","journal-title":"Future Oncol"},{"key":"401_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.11.003","author":"K Marshall","year":"2024","unstructured":"Marshall K, Mastro M, Nankervis B, Shahid S, Ciasullo G, Smith T, et al. Rapid manufacture of low-seed CAR-T cells in a GMP-grade hollow-fiber bioreactor platform. Cytotherapy. 2024. https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.003.","journal-title":"Cytotherapy"},{"key":"401_CR103","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp S, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"key":"401_CR104","doi-asserted-by":"publisher","unstructured":"Bedoya DM, Dutoit V, Migliorini D. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.720082.","DOI":"10.3389\/fimmu.2021.720082"},{"key":"401_CR105","doi-asserted-by":"publisher","unstructured":"Morgan M, B\u00fcning H, Sauer M, Schambach A. Use of Cell and Genome Modification Technologies to Generate Improved \u201cOff-the-Shelf\u201d CAR T and CAR NK Cells. Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.01965.","DOI":"10.3389\/fimmu.2020.01965"},{"key":"401_CR106","doi-asserted-by":"publisher","unstructured":"Dimitri A, Herbst F, Fraietta J. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21. https:\/\/doi.org\/10.1186\/s12943-022-01559-z.","DOI":"10.1186\/s12943-022-01559-z"},{"key":"401_CR107","doi-asserted-by":"publisher","unstructured":"Yoo J, Lai J, Prochazka L, Martinez E, Saxby C, Cadell M, et al. Abstract 4809: Preclinical characterization of an iPSC-derived allogeneic CD19\/CD20 CAR-T cell designed to address multiple limitations of current CAR-Ts. Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1538-7445.am2025-4809.","DOI":"10.1158\/1538-7445.am2025-4809"},{"key":"401_CR108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116843","author":"R Clarke","year":"2018","unstructured":"Clarke R, Stegen S, Chang CW, Husain M, Lai YS, Peralta E, et al. Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies. Blood. 2018. https:\/\/doi.org\/10.1182\/blood-2018-99-116843.","journal-title":"Blood"},{"key":"401_CR109","doi-asserted-by":"publisher","unstructured":"Fang Y, Chen Y, Li YR. Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform. Stem Cell Rep. 2025;20. https:\/\/doi.org\/10.1016\/j.stemcr.2025.102515.","DOI":"10.1016\/j.stemcr.2025.102515"},{"key":"401_CR110","doi-asserted-by":"publisher","unstructured":"Piscopo N, Mueller K, Das A, Hematti P, Murphy W, Palecek S, et al. Bioengineering Solutions for Manufacturing Challenges in CAR T Cells. Biotechnol J. 2018;13. https:\/\/doi.org\/10.1002\/biot.201700095.","DOI":"10.1002\/biot.201700095"},{"key":"401_CR111","doi-asserted-by":"crossref","unstructured":"Wang S, Yang Y, Ma P, Zha Y, Zhang J, Lei A, et al. CAR-macrophage: An extensive immune enhancer to fight cancer. EBioMedicine. 2022;76:1\u20133.","DOI":"10.1016\/j.ebiom.2022.103873"},{"key":"401_CR112","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36688","volume":"7","author":"MA Morrissey","year":"2018","unstructured":"Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018;7:e36688.","journal-title":"Elife"},{"issue":"10","key":"401_CR113","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121(10):837\u201345.","journal-title":"Br J Cancer"},{"issue":"8","key":"401_CR114","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"401_CR115","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13(1):153.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"401_CR116","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","volume":"21","author":"H Zhang","year":"2024","unstructured":"Zhang H, Huo Y, Zheng W, Li P, Li H, Zhang L, et al. Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors. Cell Mol Immunol. 2024;21(11):1335\u201349.","journal-title":"Cell Mol Immunol"},{"issue":"43","key":"401_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33(43):2103258.","journal-title":"Adv Mater"},{"key":"401_CR118","doi-asserted-by":"publisher","first-page":"1464218","DOI":"10.3389\/fcell.2024.1464218","volume":"12","author":"T Huang","year":"2024","unstructured":"Huang T, Bei C, Hu Z, Li Y. CAR-macrophage: breaking new ground in cellular immunotherapy. Front Cell Dev Biol. 2024;12:1464218.","journal-title":"Front Cell Dev Biol"},{"key":"401_CR119","doi-asserted-by":"publisher","unstructured":"Chettri D, Satapathy BP, Yadav R, Uttam V, Jain A, Prakash H. CAR-macrophages: tailoring cancer immunotherapy. Front Immunol. 2025;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1532833.","DOI":"10.3389\/fimmu.2024.1532833"},{"key":"401_CR120","doi-asserted-by":"publisher","unstructured":"Peng M, Zhu Y, Hu Y, Huang W. Advances in the regulation of macrophage polarization by the tumor microenvironment. Discover Oncol. 2025;16. https:\/\/doi.org\/10.1007\/s12672-025-03258-9.","DOI":"10.1007\/s12672-025-03258-9"},{"key":"401_CR121","doi-asserted-by":"publisher","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan C, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41. https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","DOI":"10.1186\/s13046-022-02327-z"},{"key":"401_CR122","doi-asserted-by":"publisher","unstructured":"Ziane-Chaouche L, Raffo-Romero A, Hajjaji N, Kobeissy F, Pinheiro D, Aboulouard S, et al. Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities. Cell Death Dis. 2024;15. https:\/\/doi.org\/10.1038\/s41419-024-07267-4.","DOI":"10.1038\/s41419-024-07267-4"},{"key":"401_CR123","doi-asserted-by":"publisher","unstructured":"Zhang Q, Sioud M. Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24087493.","DOI":"10.3390\/ijms24087493"},{"key":"401_CR124","doi-asserted-by":"publisher","unstructured":"Huo Y, Zhang H, Sa L, Zheng W, He Y, Lyu H, et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J Transl Med. 2023;21. https:\/\/doi.org\/10.1186\/s12967-023-04061-2.","DOI":"10.1186\/s12967-023-04061-2"},{"key":"401_CR125","doi-asserted-by":"publisher","unstructured":"Chupradit K, Muneekaew S, Wattanapanitch M. Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers. Cancer Immunol Immunother. 2024;73. https:\/\/doi.org\/10.1007\/s00262-024-03759-6.","DOI":"10.1007\/s00262-024-03759-6"},{"key":"401_CR126","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2024-5250","author":"M Boyer","year":"2024","unstructured":"Boyer M, Townsend M, Phares T, Blaszczak A, Garlick R, Katschke K, et al. Abstract 5250: Chimeric antigen receptor macrophages (MOTO CARs) driving repolarization of macrophages in solid tumors. Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.am2024-5250.","journal-title":"Cancer Res"},{"issue":"1","key":"401_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152863","volume":"230","author":"Q Si","year":"2024","unstructured":"Si Q, Yang L, Liu J, Liu H, Bu R, Cui N. Nucleotide receptor P2X7\/STAT6 pathway regulates macrophage M2 polarization and its application in CAR-T immunotherapy. Immunobiology. 2024;230(1):152863. https:\/\/doi.org\/10.1016\/j.imbio.2024.152863.","journal-title":"Immunobiology"},{"key":"401_CR128","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","volume":"18","author":"J Zhang","year":"2022","unstructured":"Zhang J, Webster S, Duffin B, Bernstein M, Steill J, Swanson S, et al. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Rep. 2022;18:585\u201396. https:\/\/doi.org\/10.1016\/j.stemcr.2022.12.012.","journal-title":"Stem Cell Rep"},{"key":"401_CR129","doi-asserted-by":"publisher","unstructured":"Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13. https:\/\/doi.org\/10.1186\/s13045-020-00983-2.","DOI":"10.1186\/s13045-020-00983-2"},{"key":"401_CR130","doi-asserted-by":"publisher","unstructured":"Su S, Lei A, Wang X, Lu H, Wang S, Yang Y, et al. Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies. Cells. 2022;11. https:\/\/doi.org\/10.3390\/cells11101652.","DOI":"10.3390\/cells11101652"},{"key":"401_CR131","doi-asserted-by":"publisher","unstructured":"Abdin S, Paasch D, Kloos A, Oliveira MC, Jang MS, Ackermann M, et al. Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia. J Immunother Cancer. 2023;11. https:\/\/doi.org\/10.1136\/jitc-2023-007705.","DOI":"10.1136\/jitc-2023-007705"},{"key":"401_CR132","doi-asserted-by":"publisher","unstructured":"Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark Res. 2023;11. https:\/\/doi.org\/10.1186\/s40364-023-00537-x.","DOI":"10.1186\/s40364-023-00537-x"},{"issue":"43","key":"401_CR133","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy. Adv Mater. 2021;33(43):e2103258. https:\/\/doi.org\/10.1002\/adma.202103258.","journal-title":"Adv Mater"},{"key":"401_CR134","doi-asserted-by":"publisher","unstructured":"Reiss K, Townsend M, Yuan Y, Dees E, Ueno NT, Pohlmann P, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03495-z.","DOI":"10.1038\/s41591-025-03495-z"},{"key":"401_CR135","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-po2-04-08","author":"Y Abdou","year":"2024","unstructured":"Abdou Y, Mortimer J, Pohlmann P, Johnson M, Maziarz R, Specht J, et al. Abstract PO2-04-08: translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 positive metastatic breast cancer and other HER2 overexpressing solid tumors. Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.sabcs23-po2-04-08.","journal-title":"Cancer Res"},{"key":"401_CR136","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-ct241","author":"Y Abdou","year":"2023","unstructured":"Abdou Y, Dees E, Mortimer J, Ueno N, Johnson M, Maziarz R, et al. Abstract CT241: a phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.am2023-ct241.","journal-title":"Cancer Res"},{"key":"401_CR137","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.tps2666","author":"Y Abdou","year":"2023","unstructured":"Abdou Y, Dees E, Mortimer J, Pohlmann P, Johnson M, Maziarz R, et al. A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.tps2666.","journal-title":"J Clin Oncol"},{"key":"401_CR138","doi-asserted-by":"publisher","unstructured":"Wang S, Yang Y, J P, Zha Y, Zhang J, Lei A, et al. CAR-macrophage: An extensive immune enhancer to fight cancer. EBioMedicine. 2022;76. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103873.","DOI":"10.1016\/j.ebiom.2022.103873"},{"key":"401_CR139","doi-asserted-by":"publisher","unstructured":"Li J, Chen P, Wenxue. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13. https:\/\/doi.org\/10.1186\/s40164-024-00549-9.","DOI":"10.1186\/s40164-024-00549-9"},{"issue":"1","key":"401_CR140","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 2024;10(1):40.","journal-title":"Cell Death Discov"},{"issue":"1","key":"401_CR141","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and current directions. Cell Death Discov. 2024;10(1):318.","journal-title":"Cell Death Discov"},{"key":"401_CR142","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"O Dagher","year":"2023","unstructured":"Dagher O, Posey A. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24:1994\u20132007. https:\/\/doi.org\/10.1038\/s41590-023-01659-y.","journal-title":"Nat Immunol"},{"key":"401_CR143","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob M, Barington T. The clinical landscape of CAR NK cells. Exp Hematol Oncol. 2025;14. https:\/\/doi.org\/10.1186\/s40164-025-00633-8.","DOI":"10.1186\/s40164-025-00633-8"},{"key":"401_CR144","doi-asserted-by":"publisher","unstructured":"Xie G, Dong H, Liang Y, Ham J, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975.","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"401_CR145","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","volume":"28","author":"N Albinger","year":"2021","unstructured":"Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28:513\u201327. https:\/\/doi.org\/10.1038\/s41434-021-00246-w.","journal-title":"Gene Ther"},{"key":"401_CR146","doi-asserted-by":"publisher","unstructured":"Lu H, Zhao X, Li Z, Hu Y, Wang H. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.720501.","DOI":"10.3389\/fonc.2021.720501"},{"key":"401_CR147","doi-asserted-by":"publisher","unstructured":"Yang R, Yang Y, Liu R, Wang Y, Yang R, He A. Advances in CAR-NK cell therapy for hematological malignancies. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1414264.","DOI":"10.3389\/fimmu.2024.1414264"},{"key":"401_CR148","doi-asserted-by":"publisher","unstructured":"Marofi F, Saleh M, Rahman H, Suksatan W, Al-Gazally M, Kamal W, et al. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res Ther. 2021;12. https:\/\/doi.org\/10.1186\/s13287-021-02462-y.","DOI":"10.1186\/s13287-021-02462-y"},{"key":"401_CR149","doi-asserted-by":"publisher","unstructured":"W\u0142odarczyk M, Pyrzynska B. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer. Cancers. 2022;15. https:\/\/doi.org\/10.3390\/cancers15010117.","DOI":"10.3390\/cancers15010117"},{"key":"401_CR150","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Ba\u015far R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384. https:\/\/doi.org\/10.1038\/s41591-023-02785-8.","journal-title":"Nat Med"},{"key":"401_CR151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202988","author":"W Qian","year":"2024","unstructured":"Qian W, Lei W, Liu H, Chen W, Liang Y, Sun YE, et al. Safety and feasibility of a 41BB co-stimulated CD19 CAR-NK cell therapy in refractory\/relapsed large B-cell lymphoma. Blood. 2024. https:\/\/doi.org\/10.1182\/blood-2024-202988.","journal-title":"Blood"},{"key":"401_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117024","volume":"177","author":"M Bahramloo","year":"2024","unstructured":"Bahramloo M, Shahabi SA, Kalarestaghi H, Rafat A, Mazloumi Z, Samimifar A, et al. CAR-NK cell therapy in AML: current challenges and advantage. Biomed Pharmacother. 2024;177:117024.","journal-title":"Biomed Pharmacother"},{"key":"401_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2024.103106","volume":"87","author":"A L\u00f3pez-Arredondo","year":"2024","unstructured":"L\u00f3pez-Arredondo A, Cruz-Cardenas JA, C\u00e1zares-Preciado JA, Timmins NE, Brunck ME. Neutrophils, an emerging new therapeutic platform. Curr Opin Biotechnol. 2024;87:103106.","journal-title":"Curr Opin Biotechnol"},{"issue":"4","key":"401_CR154","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21(4):315\u201331.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"401_CR155","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","volume":"25","author":"MC Burger","year":"2023","unstructured":"Burger MC, Forster MT, Romanski A, Stra\u00dfheimer F, Macas J, Zeiner PS, et al. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol. 2023;25(11):2058\u201371.","journal-title":"Neuro Oncol"},{"key":"401_CR156","unstructured":"Bhattarai SKaN. CAR-NK cells can mediate inflammatory toxicities in vitro. 2023 FDA Science Forum, Center for Biologics Evaluation and Research. 2023. https:\/\/www.fda.gov\/science-research\/fda-science-forum\/car-nk-cells-can-mediate-inflammatory-toxicities-vitro."},{"key":"401_CR157","doi-asserted-by":"publisher","unstructured":"Valeri A, Garc\u00eda-Ortiz A, Castellano E, C\u00f3rdoba L, Maroto-Mart\u00edn E, Encinas J, et al. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.953849.","DOI":"10.3389\/fimmu.2022.953849"},{"key":"401_CR158","doi-asserted-by":"publisher","unstructured":"Luo J, Guo M, Huang M, Liu Y, Qian Y, Liu Q, et al. Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation. Signal Transduct Target Ther. 2025;10. https:\/\/doi.org\/10.1038\/s41392-025-02158-2.","DOI":"10.1038\/s41392-025-02158-2"},{"issue":"11","key":"401_CR159","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13683","volume":"57","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li J, Wang Z, Liu Y, Wang T, Zhang M, et al. Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity. Cell Prolif. 2024;57(11):e13683.","journal-title":"Cell Prolif"},{"key":"401_CR160","doi-asserted-by":"publisher","unstructured":"Maia A, Tarannum M, L\u00e9rias J, Piccinelli S, Borrego LM, Maeurer M, et al. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy. Cells. 2024;13. https:\/\/doi.org\/10.3390\/cells13050451.","DOI":"10.3390\/cells13050451"},{"key":"401_CR161","doi-asserted-by":"publisher","unstructured":"Gong Y, Wolterink RK, Wang J, Bos G, Germeraad W. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14. https:\/\/doi.org\/10.1186\/s13045-021-01083-5.","DOI":"10.1186\/s13045-021-01083-5"},{"key":"401_CR162","doi-asserted-by":"publisher","unstructured":"Alonso-Camino V, Sullivan A, Mirsch W. Abstract LB030: Efficient feeder cell-free in vitro expansion of NK cells for CAR-NK therapies using human platelet lysate. Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1538-7445.am2025-lb030.","DOI":"10.1158\/1538-7445.am2025-lb030"},{"key":"401_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115123","volume":"165","author":"X Lin","year":"2023","unstructured":"Lin X, Sun Y, Dong X, Liu Z, Sugimura R, Xie G. Ipsc-derived CAR-NK cells for cancer immunotherapy. Biomed Pharmacother. 2023;165:115123. https:\/\/doi.org\/10.1016\/j.biopha.2023.115123.","journal-title":"Biomed Pharmacother"},{"key":"401_CR164","doi-asserted-by":"publisher","unstructured":"Kim H. Overcoming Immune Barriers in Allogeneic CAR-NK Therapy: From Multiplex Gene Editing to AI-Driven Precision Design. Biomolecules. 2025;15. https:\/\/doi.org\/10.3390\/biom15070935.","DOI":"10.3390\/biom15070935"},{"issue":"6","key":"401_CR165","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/ejh.13170","volume":"101","author":"K Kriegsmann","year":"2018","unstructured":"Kriegsmann K, Kriegsmann M, von Bergwelt-Baildon M, Cremer M, Witzens-Harig M. NKT cells\u2014new players in CAR cell immunotherapy? Eur J Haematol. 2018;101(6):750\u20137.","journal-title":"Eur J Haematol"},{"issue":"11","key":"401_CR166","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41409-020-0926-1","volume":"55","author":"VA Fabrizio","year":"2020","unstructured":"Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, et al. Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2020;55(11):2160\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"401_CR167","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756.","journal-title":"Biol Blood Marrow Transplant"},{"key":"401_CR168","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/HS9.0000000000000220","volume":"3","author":"A Karadimitris","year":"2019","unstructured":"Karadimitris A, Ripoll-Fiol C, Guerra JC. Invariant NKT cells as a platform for CAR immunotherapy and prevention of acute graft-versus-host disease. HemaSphere. 2019;3:31\u20134.","journal-title":"HemaSphere"},{"issue":"8","key":"401_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082365","volume":"19","author":"B Simon","year":"2018","unstructured":"Simon B, Wiesinger M, M\u00e4rz J, Wistuba-Hamprecht K, Weide B, Schuler-Thurner B, et al. The generation of CAR-transfected natural killer T cells for the immunotherapy of melanoma. Int J Mol Sci. 2018;19(8):2365.","journal-title":"Int J Mol Sci"},{"key":"401_CR170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149712","volume":"138","author":"CA Ramos","year":"2021","unstructured":"Ramos CA, Courtney AN, Robinson SN, Dakhova O, Lulla PD, Kamble R, et al. Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: an interim analysis. Blood. 2021;138:2819.","journal-title":"Blood"},{"issue":"6","key":"401_CR171","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.ymthe.2024.04.005","volume":"32","author":"YR Li","year":"2024","unstructured":"Li YR, Zhou Y, Yu J, Zhu Y, Lee D, Zhu E, et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol Ther. 2024;32(6):1849\u201374. https:\/\/doi.org\/10.1016\/j.ymthe.2024.04.005.","journal-title":"Mol Ther"},{"issue":"8","key":"401_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100677","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025;6(8):100677. https:\/\/doi.org\/10.1016\/j.medj.2025.100677.","journal-title":"Med"},{"key":"401_CR173","doi-asserted-by":"crossref","unstructured":"Hay AE, Cheung MC. CAR T-cells: costs, comparisons, and commentary. Taylor & Francis; 2019:613-5.","DOI":"10.1080\/13696998.2019.1582059"},{"issue":"4","key":"401_CR174","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"A Rotolo","year":"2018","unstructured":"Rotolo A, Caputo VS, Holubova M, Baxan N, Dubois O, Chaudhry MS, et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell. 2018;34(4):596-610.e11. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.017.","journal-title":"Cancer Cell"},{"issue":"21","key":"401_CR175","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","volume":"27","author":"F Simonetta","year":"2021","unstructured":"Simonetta F, Lohmeyer JK, Hirai T, Maas-Bauer K, Alvarez M, Wenokur AS, et al. Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming. Clin Cancer Res. 2021;27(21):6054\u201364.","journal-title":"Clin Cancer Res"},{"key":"401_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-01077-w","author":"YR Li","year":"2025","unstructured":"Li YR, Zhou K, Lee D, Zhu Y, Halladay T, Yu J, et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Nat Protoc. 2025. https:\/\/doi.org\/10.1038\/s41596-024-01077-w.","journal-title":"Nat Protoc"},{"key":"401_CR177","doi-asserted-by":"publisher","unstructured":"Li YR, Zhou Y, Kim Y, Zhu Y, Feiyang, Yu J, et al. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021;2. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100449.","DOI":"10.1016\/j.xcrm.2021.100449"},{"key":"401_CR178","doi-asserted-by":"publisher","unstructured":"Lyu Z, Niu S, Fang Y, Chen Y, Li YR, Yang L. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Exp Hematol Oncol. 2025;14. https:\/\/doi.org\/10.1186\/s40164-025-00654-3.","DOI":"10.1186\/s40164-025-00654-3"},{"issue":"2","key":"401_CR179","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.trecan.2016.12.006","volume":"3","author":"EB Eruslanov","year":"2017","unstructured":"Eruslanov EB, Singhal S, Albelda SM. Mouse versus human neutrophils in cancer: a major knowledge gap. Trends Cancer. 2017;3(2):149\u201360.","journal-title":"Trends Cancer"},{"issue":"6","key":"401_CR180","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/cncr.26456","volume":"118","author":"M Ilie","year":"2012","unstructured":"Ilie M, Hofman V, Ortholan C, Bonnetaud C, Co\u00eblle C, Mouroux J, et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 2012;118(6):1726\u201337.","journal-title":"Cancer"},{"issue":"9","key":"401_CR181","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485\u2013503.","journal-title":"Nat Rev Cancer"},{"key":"401_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107556","volume":"212","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Rahmy S, Liu Z, Zhang C, Lu X. Rational targeting of immunosuppressive neutrophils in cancer. Pharmacol Ther. 2020;212:107556.","journal-title":"Pharmacol Ther"},{"key":"401_CR183","doi-asserted-by":"publisher","unstructured":"Chang Y, Syahirah R, Wang X, Jin G, Torregrosa-Allen S, Elzey BD, et al. Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy. Cell Rep. 2022;40(3). https:\/\/doi.org\/10.1016\/j.celrep.2022.111128.","DOI":"10.1016\/j.celrep.2022.111128"},{"key":"401_CR184","doi-asserted-by":"publisher","unstructured":"Kargl J, Zhu X, Zhang H, Yang GH, Friesen TJ, Shipley M, et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight. 2019;4(24):e130850, 1\u201316.\u00a0https:\/\/doi.org\/10.1172\/jci.insight.130850.","DOI":"10.1172\/jci.insight.130850"},{"issue":"13","key":"401_CR185","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","volume":"23","author":"HL Matlung","year":"2018","unstructured":"Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 2018;23(13):3946-59.e6.","journal-title":"Cell Rep"},{"key":"401_CR186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02155","volume":"10","author":"P Lecot","year":"2019","unstructured":"Lecot P, Sarabi M, Pereira Abrantes M, Mussard J, Koenderman L, Caux C, et al. Neutrophil heterogeneity in cancer: from biology to therapies. Front Immunol. 2019;10:2155.","journal-title":"Front Immunol"},{"issue":"4","key":"401_CR187","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.celrep.2014.12.039","volume":"10","author":"JY Sagiv","year":"2015","unstructured":"Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10(4):562\u201373.","journal-title":"Cell Rep"},{"issue":"35","key":"401_CR188","doi-asserted-by":"publisher","first-page":"21598","DOI":"10.1073\/pnas.2008112117","volume":"117","author":"Y Itatani","year":"2020","unstructured":"Itatani Y, Yamamoto T, Zhong C, Molinolo AA, Ruppel J, Hegde P, et al. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc Natl Acad Sci U S A. 2020;117(35):21598\u2013608.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"401_CR189","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1182\/blood-2010-01-265942","volume":"116","author":"DH McDermott","year":"2010","unstructured":"McDermott DH, De Ravin SS, Jun HS, Liu Q, Priel DAL, Noel P, et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood. 2010;116(15):2793\u2013802.","journal-title":"Blood"},{"issue":"1","key":"401_CR190","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","volume":"14","author":"Y Chang","year":"2023","unstructured":"Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14(1):2266.","journal-title":"Nat Commun"},{"issue":"7\u20138","key":"401_CR191","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1515\/hsz-2023-0317","volume":"405","author":"CA Tsiverioti","year":"2024","unstructured":"Tsiverioti CA, Gottschlich A, Trefny M, Theurich S, Anders HJ, Kroiss M, et al. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies. Biol Chem. 2024;405(7\u20138):485\u2013515. https:\/\/doi.org\/10.1515\/hsz-2023-0317.","journal-title":"Biol Chem"},{"key":"401_CR192","doi-asserted-by":"publisher","unstructured":"Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14. https:\/\/doi.org\/10.1038\/s41467-023-37872-4.","DOI":"10.1038\/s41467-023-37872-4"},{"key":"401_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111128","volume":"40","author":"Y Chang","year":"2022","unstructured":"Chang Y, Syahirah R, Wang X, Jin G, Torregrosa-Allen S, Elzey B, et al. Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy. Cell Rep. 2022;40:111128. https:\/\/doi.org\/10.1016\/j.celrep.2022.111128.","journal-title":"Cell Rep"},{"key":"401_CR194","doi-asserted-by":"publisher","unstructured":"Liang Y, Xu Q, Gao Q. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1291619.","DOI":"10.3389\/fimmu.2023.1291619"},{"key":"401_CR195","doi-asserted-by":"publisher","unstructured":"Zhang J, Gu J, Wang X, Ji C, Yu D, Wang M, et al. Engineering and Targeting Neutrophils for Cancer Therapy. Adv Mater. 2024;36. https:\/\/doi.org\/10.1002\/adma.202310318.","DOI":"10.1002\/adma.202310318"},{"key":"401_CR196","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bioactmat.2025.06.025","volume":"52","author":"B Liu","year":"2025","unstructured":"Liu B, Shen J, Wu Y, Wong CF, Hei TY, Li JWT, et al. Novel strategy for tumor immunotherapy using FITC-folate bispecific adapter bridged CAR immune cell cocktails. Bioact Mater. 2025;52:529\u201340. https:\/\/doi.org\/10.1016\/j.bioactmat.2025.06.025.","journal-title":"Bioact Mater"},{"key":"401_CR197","doi-asserted-by":"publisher","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16. https:\/\/doi.org\/10.1186\/s13045-023-01492-8.","DOI":"10.1186\/s13045-023-01492-8"},{"key":"401_CR198","doi-asserted-by":"publisher","unstructured":"Qin V, D\u2019Souza C, Neeson P, Zhu J. Chimeric Antigen Receptor beyond CAR-T Cells. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/cancers13030404.","DOI":"10.3390\/cancers13030404"},{"key":"401_CR199","doi-asserted-by":"publisher","unstructured":"Li YR, Zhu Y, Chen Y, Yang L. The clinical landscape of CAR-engineered unconventional T cells. Trends Cancer. 2025. https:\/\/doi.org\/10.1016\/j.trecan.2025.03.001.","DOI":"10.1016\/j.trecan.2025.03.001"},{"issue":"2","key":"401_CR200","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.canlet.2016.07.001","volume":"380","author":"HR Mirzaei","year":"2016","unstructured":"Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG. Prospects for chimeric antigen receptor (CAR) \u03b3\u03b4 T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 2016;380(2):413\u201323. https:\/\/doi.org\/10.1016\/j.canlet.2016.07.001.","journal-title":"Cancer Lett"},{"key":"401_CR201","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2017","unstructured":"Capsomidis A, Benthall G, Van Acker H, Fisher J, Kramer A, Abeln Z, et al. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation. Mol Ther. 2017;26:354\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.001.","journal-title":"Mol Ther"},{"key":"401_CR202","doi-asserted-by":"publisher","unstructured":"Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, et al. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia. Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.01347.","DOI":"10.3389\/fimmu.2020.01347"},{"issue":"6","key":"401_CR203","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/vaccines13060654","volume":"13","author":"Y Xian","year":"2025","unstructured":"Xian Y, Wen L. CAR beyond \u03b1\u03b2 T cells: unleashing NK cells, macrophages, and \u03b3\u03b4 T lymphocytes against solid tumors. Vaccines. 2025;13(6):654.","journal-title":"Vaccines"},{"key":"401_CR204","doi-asserted-by":"publisher","unstructured":"Luginbuehl V, Abraham E, Kovar K, Flaaten R, M\u00fcller A. Better by design: What to expect from novel CAR-engineered cell therapies? Biotechnol Adv. 2022:107917. https:\/\/doi.org\/10.1016\/j.biotechadv.2022.107917.","DOI":"10.1016\/j.biotechadv.2022.107917"},{"issue":"22","key":"401_CR205","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","volume":"4","author":"R Ba\u015far","year":"2020","unstructured":"Ba\u015far R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Adv. 2020;4(22):5868\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2020002547.","journal-title":"Blood Adv"},{"key":"401_CR206","doi-asserted-by":"publisher","unstructured":"Wen R, Li B, Wu F, Mao J, Azad T, Wang Y, et al. Chimeric antigen receptor cell therapy: A revolutionary approach transforming cancer treatment to autoimmune disease therapy. Autoimmun Rev. 2025:103859. https:\/\/doi.org\/10.1016\/j.autrev.2025.103859.","DOI":"10.1016\/j.autrev.2025.103859"},{"key":"401_CR207","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611366","volume":"12","author":"Z Yan","year":"2021","unstructured":"Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol. 2021;12:611366.","journal-title":"Front Immunol"},{"key":"401_CR208","unstructured":"Anand J. Incidence and management of Cytokine release syndrome in CAR-T cell therapy for solid tumors: A systematic review of phase I trials. J Cancer Immunol Ther 2024; 7 (5): 235 1 J Cancer Immunol Ther 2024 Volume 7 Issue 5 Review Article https:\/\/www.alliedacademies.org\/journal-cancer-immunology-therapy."},{"issue":"4","key":"401_CR209","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/1535-7163.MCT-24-0721","volume":"24","author":"A Zhang","year":"2025","unstructured":"Zhang A, Yang X, Zhang Y, Yu X, Mu W, Wei J. Unlocking the potential of CAR-NK cell therapy: overcoming barriers and challenges in the treatment of myeloid malignancies. Mol Cancer Ther. 2025;24(4):536\u201349.","journal-title":"Mol Cancer Ther"},{"key":"401_CR210","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720501","volume":"11","author":"H Lu","year":"2021","unstructured":"Lu H, Zhao X, Li Z, Hu Y, Wang H. From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies. Front Oncol. 2021;11:720501.","journal-title":"Front Oncol"},{"issue":"2","key":"401_CR211","volume":"5","author":"M Moumaris","year":"2024","unstructured":"Moumaris M. Unlocking the potential: overcoming challenges in CAR-T cell therapy for cancer treatment. J Biotechnology and Bioprocessing. 2024;5(2):2766\u2013314.","journal-title":"J Biotechnology and Bioprocessing"},{"issue":"23","key":"401_CR212","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/blood.2024026831","volume":"145","author":"L Samples","year":"2025","unstructured":"Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, et al. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025;145(23):2762\u20137.","journal-title":"Blood"},{"key":"401_CR213","doi-asserted-by":"publisher","unstructured":"Lei W, Xie M, Jiang Q, Xu NW, Li P, Liang A, et al. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/cancers13153912.","DOI":"10.3390\/cancers13153912"},{"key":"401_CR214","doi-asserted-by":"publisher","unstructured":"Yang C, Nguyen J, Yen Y. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. J Biomed Sci. 2023;30. https:\/\/doi.org\/10.1186\/s12929-023-00982-8.","DOI":"10.1186\/s12929-023-00982-8"},{"key":"401_CR215","doi-asserted-by":"publisher","unstructured":"Brudno J, Kochenderfer J. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024. https:\/\/doi.org\/10.1038\/s41571-024-00903-0.","DOI":"10.1038\/s41571-024-00903-0"},{"key":"401_CR216","doi-asserted-by":"publisher","unstructured":"Guo Z, Ding Y, Wang M, Zhai Q, Liu J, Du Q. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study. Pharmaceuticals. 2024;17. https:\/\/doi.org\/10.3390\/ph17081025.","DOI":"10.3390\/ph17081025"},{"key":"401_CR217","doi-asserted-by":"publisher","unstructured":"Hughes A, Teachey D, Diorio C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol. 2024;46. https:\/\/doi.org\/10.1007\/s00281-024-01013-w.","DOI":"10.1007\/s00281-024-01013-w"},{"key":"401_CR218","doi-asserted-by":"publisher","unstructured":"Andrea A, Chiron A, Bessoles S, Hacein-Bey-Abina S. Engineering Next-Generation CAR-T Cells for Better Toxicity Management. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21228620.","DOI":"10.3390\/ijms21228620"},{"key":"401_CR219","doi-asserted-by":"publisher","unstructured":"Dong J, Wu J, Jin Y, Zheng Z, Su T, Shao L, et al. In-depth analysis of the safety of CAR-T cell therapy for solid tumors. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1548979.","DOI":"10.3389\/fimmu.2025.1548979"},{"issue":"1","key":"401_CR220","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","volume":"14","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Niu S, Fang Y, Chen Y, Li YR, Yang L. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Exp Hematol Oncol. 2025;14(1):66. https:\/\/doi.org\/10.1186\/s40164-025-00654-3.","journal-title":"Exp Hematol Oncol"},{"key":"401_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.11.035","author":"YR Li","year":"2024","unstructured":"Li YR, Fang Y, Niu S, Chen Y, Lyu Z, Yang L. Managing Allorejection in Off-the-Shelf CAR-Engineered Cell Therapies. Mol Ther. 2024. https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.035.","journal-title":"Mol Ther"},{"key":"401_CR222","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"YX Hu","year":"2022","unstructured":"Hu YX, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995\u20131007. https:\/\/doi.org\/10.1038\/s41422-022-00721-y.","journal-title":"Cell Res"},{"key":"401_CR223","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/08830185.2021.1984449","volume":"41","author":"V Mansouri","year":"2021","unstructured":"Mansouri V, Yazdanpanah N, Rezaei N. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. Int Rev Immunol. 2021;41:649\u201368. https:\/\/doi.org\/10.1080\/08830185.2021.1984449.","journal-title":"Int Rev Immunol"},{"issue":"10","key":"401_CR224","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","volume":"26","author":"AJ Hou","year":"2024","unstructured":"Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, et al. IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro Oncol. 2024;26(10):1850\u201366.","journal-title":"Neuro Oncol"},{"issue":"1","key":"401_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05907-z","volume":"23","author":"S Wu","year":"2025","unstructured":"Wu S, Wei Y, Qiu Y, Ai K, Chen M, Wang H, et al. Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt\/\u03b2-catenin pathway. J Transl Med. 2025;23(1):494. https:\/\/doi.org\/10.1186\/s12967-024-05907-z.","journal-title":"J Transl Med"},{"issue":"8","key":"401_CR226","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/jci83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov D, Jones D, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130\u201344. https:\/\/doi.org\/10.1172\/jci83092.","journal-title":"J Clin Invest"},{"key":"401_CR227","doi-asserted-by":"publisher","unstructured":"Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024;5. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101400.","DOI":"10.1016\/j.xcrm.2024.101400"},{"issue":"9","key":"401_CR228","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103508","volume":"9","author":"M Shao","year":"2022","unstructured":"Shao M, Teng X, Guo X, Zhang H, Huang Y, Cui J, et al. Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE-Calcineurin-NFAT and Glycolysis Pathways. Adv Sci. 2022;9(9):e2103508. https:\/\/doi.org\/10.1002\/advs.202103508.","journal-title":"Adv Sci"},{"key":"401_CR229","doi-asserted-by":"publisher","unstructured":"Biederst\u00e4dt A, Bassermann F, Hecker JS. Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1585556.","DOI":"10.3389\/fimmu.2025.1585556"},{"issue":"1","key":"401_CR230","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Saleh MM, Rahman HS, Suksatan W, Al-Gazally ME, Abdelbasset WK, et al. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res Ther. 2021;12(1):374. https:\/\/doi.org\/10.1186\/s13287-021-02462-y.","journal-title":"Stem Cell Res Ther"},{"key":"401_CR231","doi-asserted-by":"publisher","unstructured":"Li S, Jing J, Chen Y, Chi E, Wang B, Xie Z, et al. Precision sniper for solid tumors: CAR-NK cell therapy. Cancer Immunol Immunother. 2025;74. https:\/\/doi.org\/10.1007\/s00262-025-04106-z.","DOI":"10.1007\/s00262-025-04106-z"},{"key":"401_CR232","doi-asserted-by":"publisher","unstructured":"Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L. CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1574742.","DOI":"10.3389\/fimmu.2025.1574742"},{"key":"401_CR233","doi-asserted-by":"publisher","unstructured":"Jia H, Yang H, Xiong H, Luo KQ. NK cell exhaustion in the tumor microenvironment. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1303605.","DOI":"10.3389\/fimmu.2023.1303605"},{"key":"401_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107637","volume":"212","author":"Y Ren","year":"2025","unstructured":"Ren Y, Xue M, Hui X, Liu X, Farooq MA, Chen Y, et al. Chimeric cytokine receptor TGF-\u03b2 R\u2161\/IL-21R improves CAR-NK cell function by reversing the immunosuppressive tumor microenvironment of gastric cancer. Pharmacol Res. 2025;212:107637. https:\/\/doi.org\/10.1016\/j.phrs.2025.107637.","journal-title":"Pharmacol Res"},{"key":"401_CR235","doi-asserted-by":"publisher","unstructured":"Steggerda S, Bennett M, Chen J, Emberley E, Huang T, Janes J, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017;5. https:\/\/doi.org\/10.1186\/s40425-017-0308-4.","DOI":"10.1186\/s40425-017-0308-4"},{"issue":"9","key":"401_CR236","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.cir-21-1052","volume":"10","author":"F Souza-Fonseca-Guimaraes","year":"2022","unstructured":"Souza-Fonseca-Guimaraes F, Rossi GR, Dagley LF, Foroutan M, McCulloch TR, Yousef J, et al. TGF\u03b2 and CIS inhibition overcomes NK-cell suppression to restore antitumor immunity. Cancer Immunol Res. 2022;10(9):1047\u201354. https:\/\/doi.org\/10.1158\/2326-6066.cir-21-1052.","journal-title":"Cancer Immunol Res"},{"issue":"415","key":"401_CR237","doi-asserted-by":"publisher","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","volume":"9","author":"S Viel","year":"2016","unstructured":"Viel S, Mar\u00e7ais A, Guimaraes FSF, Loftus R, Rabilloud J, Grau M, et al. TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal. 2016;9(415):ra19-ra. https:\/\/doi.org\/10.1126\/scisignal.aad1884.","journal-title":"Sci Signal"},{"issue":"1","key":"401_CR238","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"issue":"1","key":"401_CR239","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.","journal-title":"J Exp Clin Cancer Res"},{"key":"401_CR240","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez de Larrea C, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma. Blood Cancer Discov. 2020;1(2):146\u201354.","DOI":"10.1158\/2643-3230.BCD-20-0020"},{"key":"401_CR241","doi-asserted-by":"publisher","unstructured":"Kalyane D, Yu J, Admasu T, Michel M, Wang H, Murali R. Abstract A048: Targeting M2 macrophage polarization: The anti-tumor effects of IL-4\/IL-13 blocking peptide (KROS-401) and iron oxide nanoparticles. Cancer Immunol Res. 2025. https:\/\/doi.org\/10.1158\/2326-6074.io2025-a048.","DOI":"10.1158\/2326-6074.io2025-a048"},{"issue":"1","key":"401_CR242","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1447-y","volume":"10","author":"F Liu","year":"2019","unstructured":"Liu F, Qiu H, Xue M, Zhang S, Zhang X, Xu J, et al. Msc-secreted TGF-\u03b2 regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt\/FoxO1 pathway. Stem Cell Res Ther. 2019;10(1):345. https:\/\/doi.org\/10.1186\/s13287-019-1447-y.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"401_CR243","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1042\/cs20201236","volume":"135","author":"J van den Bulk","year":"2021","unstructured":"van den Bulk J, de Miranda NFCC, ten Dijke P. Therapeutic targeting of TGF-\u03b2 in cancer: hacking a master switch of immune suppression. Clin Sci. 2021;135(1):35\u201352. https:\/\/doi.org\/10.1042\/cs20201236.","journal-title":"Clin Sci"},{"issue":"11","key":"401_CR244","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020;26(11):1686\u201390.","journal-title":"Nat Med"},{"issue":"11","key":"401_CR245","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wang Y, Dou Z, Delfanti G, Kyewalabye K, Phyu S, et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat Cancer. 2024;5(11):1607\u201321.","journal-title":"Nat Cancer"},{"key":"401_CR246","doi-asserted-by":"publisher","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941, 1\u201312.\u00a0https:\/\/doi.org\/10.1016\/j.ebiom.2022.103941.","DOI":"10.1016\/j.ebiom.2022.103941"},{"issue":"20","key":"401_CR247","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20):6106\u201315.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"401_CR248","first-page":"228","volume":"9","author":"B Liu","year":"2019","unstructured":"Liu B, Yan L, Zhou M. Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J Cancer Res. 2019;9(2):228\u201341.","journal-title":"Am J Cancer Res"},{"key":"401_CR249","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:1\u20136.","journal-title":"Biomark Res"},{"issue":"8","key":"401_CR250","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/14712598.2017.1339687","volume":"17","author":"RA Oldham","year":"2017","unstructured":"Oldham RA, Medin JA. Practical considerations for chimeric antigen receptor design and delivery. Expert Opin Biol Ther. 2017;17(8):961\u201378.","journal-title":"Expert Opin Biol Ther"},{"key":"401_CR251","doi-asserted-by":"publisher","unstructured":"Ramello M, Benza\u00efd I, Kuenzi B, Lienlaf-Moreno M, Kandell W, Santiago D, et al. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 2019;12. https:\/\/doi.org\/10.1126\/scisignal.aap9777.","DOI":"10.1126\/scisignal.aap9777"},{"key":"401_CR252","doi-asserted-by":"publisher","unstructured":"Honikel M, Olejniczak S. Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules. 2022;12. https:\/\/doi.org\/10.3390\/biom12091303.","DOI":"10.3390\/biom12091303"},{"key":"401_CR253","doi-asserted-by":"publisher","unstructured":"Salter A, Ivey R, Kennedy J, Voillet V, Rajan A, Alderman E, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11. https:\/\/doi.org\/10.1126\/scisignal.aat6753.","DOI":"10.1126\/scisignal.aat6753"},{"key":"401_CR254","doi-asserted-by":"publisher","unstructured":"Montalvo M, Bandey I, Rezvan A, Wu KL, Saeedi A, Kulkarni R, et al. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. Cell Death Dis. 2024;15. https:\/\/doi.org\/10.1038\/s41419-024-06461-8.","DOI":"10.1038\/s41419-024-06461-8"},{"key":"401_CR255","doi-asserted-by":"publisher","unstructured":"Czaplicka A, Lachota M, P\u0105czek L, Zago\u017cd\u017con R, Kaleta B. Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence. Cells. 2024;13. https:\/\/doi.org\/10.3390\/cells13010101.","DOI":"10.3390\/cells13010101"},{"issue":"1","key":"401_CR256","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04479-8","volume":"21","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu X, Liu H, Wang C, Chen Y, Wang H, et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med. 2023;21(1):654.","journal-title":"J Transl Med"},{"issue":"25","key":"401_CR257","doi-asserted-by":"publisher","first-page":"10299","DOI":"10.1073\/pnas.0703824104","volume":"104","author":"YJ Chang","year":"2007","unstructured":"Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, Fujio M, et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci U S A. 2007;104(25):10299\u2013304.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"401_CR258","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39\u201351. https:\/\/doi.org\/10.1016\/j.cell.2010.03.014.","journal-title":"Cell"},{"issue":"18","key":"401_CR259","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014;124(18):2824\u201333.","journal-title":"Blood"},{"issue":"2","key":"401_CR260","first-page":"421","volume":"40","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim M, Melief J. Pico de Coa\u00f1a Y, Wickstr\u00f6m SL, Cid-Arregui A, Kiessling R. Counteracting CAR T cell dysfunction Oncogene. 2021;40(2):421\u201335.","journal-title":"Counteracting CAR T cell dysfunction Oncogene"},{"key":"401_CR261","doi-asserted-by":"publisher","unstructured":"Zhou Z, Chen Y, Ba Y, Xu H, Zuo A, Liu S, et al. Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non\u2010Viral CAR\u2010NK Cell Engineering. Cell Prolif. 2024;58(4):e13791.\u00a0https:\/\/doi.org\/10.1111\/cpr.13791.","DOI":"10.1111\/cpr.13791"},{"key":"401_CR262","doi-asserted-by":"crossref","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59.","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"401_CR263","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156973","volume":"192","author":"M Wang","year":"2025","unstructured":"Wang M, Wang Z, Zhang G, Fan J. Interleukin-enhanced CAR-engineered immune cells in tumor immunotherapy: current insights and future perspectives. Cytokine. 2025;192:156973. https:\/\/doi.org\/10.1016\/j.cyto.2025.156973.","journal-title":"Cytokine"},{"key":"401_CR264","doi-asserted-by":"publisher","unstructured":"Benmebarek M, Karches C, Cadilha B, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20061283.","DOI":"10.3390\/ijms20061283"},{"key":"401_CR265","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1135468","volume":"10","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu Y, Kramer A, Fang Y, Wilson M, Li YR, et al. Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy. Front Med. 2023;10:1135468. https:\/\/doi.org\/10.3389\/fmed.2023.1135468.","journal-title":"Front Med"},{"issue":"4","key":"401_CR266","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006401","volume":"11","author":"MM Melssen","year":"2023","unstructured":"Melssen MM, Sheybani ND, Leick KM, Slingluff JCL. Barriers to immune cell infiltration in tumors. J Immunother Cancer. 2023;11(4):e006401.","journal-title":"J Immunother Cancer"},{"key":"401_CR267","doi-asserted-by":"publisher","unstructured":"Zhu Y, Feng J, Wan R, Huang W. CAR T cell therapy: remedies of current challenges in design, injection, infiltration and working. Drug Des Dev Ther.\u00a02023;17:1783\u201392.\u00a0https:\/\/doi.org\/10.2147\/DDDT.S413348.","DOI":"10.2147\/DDDT.S413348"},{"issue":"7_Supplement","key":"401_CR268","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-LB120","volume":"84","author":"X Wang","year":"2024","unstructured":"Wang X, Hou AJ, Christopher MA, Bulliard Y, Damiano JS. Abstract LB120: stem cell-derived ACUA CAR-NKT allogeneic cell therapies harness orthogonal mechanisms of action for the treatment of solid tumors. Cancer Res. 2024;84(7_Supplement):LB120-LB.","journal-title":"Cancer Res"},{"key":"401_CR269","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101342","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang G, Chai D, Dang Y, Zheng J, Li H. iNKT: a new avenue for CAR-based cancer immunotherapy. Transl Oncol. 2022;17:101342.","journal-title":"Transl Oncol"},{"key":"401_CR270","doi-asserted-by":"publisher","unstructured":"Wrona E, Borowiec M, Potemski P. CAR-NK Cells in the Treatment of Solid Tumors. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22115899.","DOI":"10.3390\/ijms22115899"},{"key":"401_CR271","doi-asserted-by":"publisher","unstructured":"Maalej KM, Merhi M, Inchakalody V, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22. https:\/\/doi.org\/10.1186\/s12943-023-01723-z.","DOI":"10.1186\/s12943-023-01723-z"},{"key":"401_CR272","doi-asserted-by":"publisher","unstructured":"Liu Y, Xiao L, Yang M, Chen X, Liu H, Wang Q, et al. CAR-armored-cell therapy in solid tumor treatment. J Transl Med. 2024;22. https:\/\/doi.org\/10.1186\/s12967-024-05903-3.","DOI":"10.1186\/s12967-024-05903-3"},{"issue":"14","key":"401_CR273","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273\u201390. https:\/\/doi.org\/10.7150\/thno.76854.","journal-title":"Theranostics"},{"key":"401_CR274","doi-asserted-by":"crossref","unstructured":"Zhou Z, Chen Y, Ba Y, Xu H, Zuo A, Liu S, et al. Revolutionising cancer immunotherapy: advancements and prospects in non-viral CAR-NK cell engineering. Cell Prolif. 2025;58(4):e13791.","DOI":"10.1111\/cpr.13791"},{"key":"401_CR275","doi-asserted-by":"publisher","unstructured":"Johnson A, Townsend M, O\u2019Neill K. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. Cells. 2022;11. https:\/\/doi.org\/10.3390\/cells14123626.","DOI":"10.3390\/cells14123626"},{"key":"401_CR276","doi-asserted-by":"publisher","unstructured":"Li W, Pan X, Chen L, Cui H, Mo S, Pan Y, et al. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1186383.","DOI":"10.3389\/fimmu.2023.1186383"},{"key":"401_CR277","doi-asserted-by":"publisher","unstructured":"Zhang B, Liu J, Mo Y, Zhang K, Huang B, Shang D. CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1476904.","DOI":"10.3389\/fimmu.2024.1476904"},{"key":"401_CR278","doi-asserted-by":"crossref","unstructured":"Song L, Asgharzadeh S, Salo J, Engell K, Wu Hw, Sposto R, et al. V\u03b124-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest. 2009;119(6):1524\u201336.","DOI":"10.1172\/JCI37869"},{"key":"401_CR279","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.cji.0000211321.07654.b8","volume":"30","author":"X Shen","year":"2007","unstructured":"Shen X, Zhou J, Hathcock K, Robbins P, Powell D, Rosenberg S, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007;30:123\u20139. https:\/\/doi.org\/10.1097\/01.cji.0000211321.07654.b8.","journal-title":"J Immunother"},{"key":"401_CR280","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153183","author":"E Tedone","year":"2021","unstructured":"Tedone E, Sayed M, Lai TP, Sannareddy A, Ramasamy D, Anderson L, et al. T-Cell Telomere Length As a Biomarker to Predict Outcome in Patients Receiving CAR-T Immunotherapy. Blood. 2021. https:\/\/doi.org\/10.1182\/blood-2021-153183.","journal-title":"Blood"},{"key":"401_CR281","doi-asserted-by":"publisher","unstructured":"Watkinson F, Nayar S, Rani A, Sakellariou C, Elhage O, Papaevangelou E, et al. IL-15 Upregulates Telomerase Expression and Potently Increases Proliferative Capacity of NK, NKT-Like, and CD8 T Cells. Front Immunol. 2021;11. https:\/\/doi.org\/10.3389\/fimmu.2020.594620.","DOI":"10.3389\/fimmu.2020.594620"},{"key":"401_CR282","doi-asserted-by":"publisher","DOI":"10.1172\/jci133215","author":"S Guedan","year":"2020","unstructured":"Guedan S, Madar A, Casado-Medrano V, Shaw C, Wing A, Liu F, et al. Single residue in CD28-costimulated CAR T cells limits long-term persistence and antitumor durability. J Clin Invest. 2020. https:\/\/doi.org\/10.1172\/jci133215.","journal-title":"J Clin Invest"},{"key":"401_CR283","doi-asserted-by":"publisher","unstructured":"Pietrobon V, Todd L, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-Cell Persistence. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms221910828.","DOI":"10.3390\/ijms221910828"},{"key":"401_CR284","doi-asserted-by":"publisher","unstructured":"Prinzing B, Zebley C, Petersen C, Fan Y, Anido AA, Yi Z, et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021;13. https:\/\/doi.org\/10.1126\/scitranslmed.abh0272.","DOI":"10.1126\/scitranslmed.abh0272"},{"key":"401_CR285","doi-asserted-by":"publisher","unstructured":"Dehghan F, Metanat Y, Askarizadeh M, Ahmadi E, Moradi V. Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy. Front Cell Dev Biol. 2025;12. https:\/\/doi.org\/10.3389\/fcell.2024.1511931.","DOI":"10.3389\/fcell.2024.1511931"},{"key":"401_CR286","doi-asserted-by":"publisher","unstructured":"Gao J, Liang Y, Wang L. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.888713.","DOI":"10.3389\/fimmu.2022.888713"},{"key":"401_CR287","doi-asserted-by":"publisher","unstructured":"Zhang J, Zhou XY, Hao H. Macrophage phenotype-switching in cancer. Eur J Pharmacol. 2022:175229. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175229.","DOI":"10.1016\/j.ejphar.2022.175229"},{"key":"401_CR288","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1002\/jcb.27646","volume":"120","author":"M Najafi","year":"2018","unstructured":"Najafi M, Goradel NH, Farhood B, Salehi E, Nashtaei M, Khanlarkhani N, et al. Macrophage polarity in cancer: A review. J Cell Biochem. 2018;120:2756\u201365. https:\/\/doi.org\/10.1002\/jcb.27646.","journal-title":"J Cell Biochem"},{"key":"401_CR289","doi-asserted-by":"publisher","unstructured":"Liu J, Geng XF, Hou J, Wu G. New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21. https:\/\/doi.org\/10.1186\/s12935-021-02089-2.","DOI":"10.1186\/s12935-021-02089-2"},{"key":"401_CR290","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s44321-023-00013-x","volume":"16","author":"A Bodac","year":"2023","unstructured":"Bodac A, Mayet A, Rana S, Bowler A, Roh V, et al. Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth. EMBO Mol Med. 2023;16:158\u201384. https:\/\/doi.org\/10.1038\/s44321-023-00013-x.","journal-title":"EMBO Mol Med"},{"key":"401_CR291","doi-asserted-by":"publisher","unstructured":"Vier J, Groth M, Sochalska M, Kirschnek S. The anti-apoptotic Bcl-2 family protein A1\/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK\/STAT signaling. Cell Death Dis. 2016;7. https:\/\/doi.org\/10.1038\/cddis.2016.23.","DOI":"10.1038\/cddis.2016.23"},{"key":"401_CR292","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1084\/jem.179.3.1047","volume":"179","author":"E Lagasse","year":"1994","unstructured":"Lagasse E, Weissman I. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med. 1994;179:1047\u201352. https:\/\/doi.org\/10.1084\/jem.179.3.1047.","journal-title":"J Exp Med"},{"issue":"4","key":"401_CR293","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/imm.13642","volume":"169","author":"X Yin","year":"2023","unstructured":"Yin X, He L, Guo Z. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it. Immunology. 2023;169(4):400\u201311.","journal-title":"Immunology"},{"key":"401_CR294","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24:1994\u20132007.","journal-title":"Nat Immunol"},{"issue":"5","key":"401_CR295","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1134\/S0006297924050018","volume":"89","author":"EP Minina","year":"2024","unstructured":"Minina EP, Dianov DV, Sheetikov SA, Bogolyubova AV. CAR cells beyond classical CAR T cells: functional properties and prospects of application. Biochemistry (Mosc). 2024;89(5):765\u201383.","journal-title":"Biochemistry (Mosc)"},{"key":"401_CR296","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","volume":"368","author":"T Zhang","year":"2024","unstructured":"Zhang T, Tai Z, Miao F, Zhang X, Li J, Zhu Q, et al. Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances. J Control Release. 2024;368:372\u201396.","journal-title":"J Control Release"},{"key":"401_CR297","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","volume":"11","author":"A Rodriguez-Garcia","year":"2020","unstructured":"Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJ Jr, Guedan S. CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape. Front Immunol. 2020;11:1109.","journal-title":"Front Immunol"},{"issue":"1","key":"401_CR298","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105.","journal-title":"J Hematol Oncol"},{"key":"401_CR299","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.","journal-title":"Front Immunol"},{"issue":"10","key":"401_CR300","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jcyt.2024.05.011","volume":"26","author":"D Lutskovich","year":"2024","unstructured":"Lutskovich D, Meleshko A, Katsin M. State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma. Cytotherapy. 2024;26(10):1122\u201331.","journal-title":"Cytotherapy"},{"issue":"12","key":"401_CR301","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23(12):1416\u201323.","journal-title":"Nat Med"},{"issue":"1","key":"401_CR302","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32092-8","volume":"13","author":"F Li","year":"2022","unstructured":"Li F, Zhang H, Wang W, Yang P, Huang Y, Zhang J, et al. T cell receptor \u03b2-chain-targeting chimeric antigen receptor T cells against T cell malignancies. Nat Commun. 2022;13(1):4334.","journal-title":"Nat Commun"},{"issue":"4","key":"401_CR303","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2025;43(4):506\u201315.","journal-title":"Nat Biotechnol"},{"issue":"17","key":"401_CR304","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697\u2013706.","journal-title":"Cancer Res"},{"issue":"1","key":"401_CR305","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi G, Liuzzi AR, Hotblack A, De Feo D, N\u00fa\u00f1ez N, Stowe CL, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12(1):444.","journal-title":"Nat Commun"},{"issue":"11","key":"401_CR306","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 2017;21(11):3205\u201319.","journal-title":"Cell Rep"},{"issue":"14","key":"401_CR307","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284\u201395.","journal-title":"N Engl J Med"},{"issue":"9","key":"401_CR308","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017;25(9):2214\u201324.","journal-title":"Mol Ther"},{"issue":"1","key":"401_CR309","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","volume":"42","author":"S Kaczanowska","year":"2024","unstructured":"Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2024;42(1):35-51.e8.","journal-title":"Cancer Cell"},{"issue":"571","key":"401_CR310","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd6169","volume":"12","author":"K Straathof","year":"2020","unstructured":"Straathof K, Flutter B, Wallace R, Jain N, Loka T, Depani S, et al. Antitumor activity without on-target off-tumor toxicity of GD2\u2013chimeric antigen receptor T cells in patients with neuroblastoma. Sci Transl Med. 2020;12(571):eabd6169.","journal-title":"Sci Transl Med"},{"issue":"4","key":"401_CR311","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10555-024-10214-6","volume":"43","author":"T Trautmann","year":"2024","unstructured":"Trautmann T, Yakobian N, Nguyen R. CAR T-cells for pediatric solid tumors: where to go from here? Cancer Metastasis Rev. 2024;43(4):1445\u201361.","journal-title":"Cancer Metastasis Rev"},{"issue":"7903","key":"401_CR312","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934\u201341.","journal-title":"Nature"},{"issue":"5","key":"401_CR313","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber EW, Lynn RC, Sotillo E, Lattin J, Xu P, Mackall CL. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019;3(5):711\u20137.","journal-title":"Blood Adv"},{"issue":"1","key":"401_CR314","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05724-4","volume":"22","author":"X Lin","year":"2024","unstructured":"Lin X, Liu Z, Dong X, Wang K, Sun Y, Zhang H, et al. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma. J Transl Med. 2024;22(1):929.","journal-title":"J Transl Med"},{"issue":"1","key":"401_CR315","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40164-024-00583-7","volume":"13","author":"P Yao","year":"2024","unstructured":"Yao P, Liu YG, Huang G, Hao L, Wang R. The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and current advances. Exp Hematol Oncol. 2024;13(1):118.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"401_CR316","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/cancers12040842","volume":"12","author":"AJ Petty","year":"2020","unstructured":"Petty AJ, Heyman B, Yang Y. Chimeric antigen receptor cell therapy: overcoming obstacles to battle cancer. Cancers. 2020;12(4):842.","journal-title":"Cancers"},{"key":"401_CR317","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112512","volume":"146","author":"AZ Mehrabadi","year":"2022","unstructured":"Mehrabadi AZ, Ranjbar R, Farzanehpour M, Shahriary A, Dorostkar R, Hamidinejad MA, et al. Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomed Pharmacother. 2022;146:112512.","journal-title":"Biomed Pharmacother"},{"key":"401_CR318","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305.","journal-title":"Front Immunol"},{"issue":"5","key":"401_CR319","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.xphs.2021.02.006","volume":"110","author":"S Theoharis","year":"2021","unstructured":"Theoharis S. Current state of the art of allogeneic CAR approaches\u2013pile \u2018Em high and sell\u2019em cheap. J Pharm Sci. 2021;110(5):1909\u201314.","journal-title":"J Pharm Sci"},{"key":"401_CR320","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.851877","volume":"12","author":"JK Jang","year":"2022","unstructured":"Jang JK, Pyo J, Suh CH, Park HS, Chae YK, Kim KW. Safety and efficacy of chimeric antigen receptor T-cell therapy for glioblastoma: a systemic review and meta-analysis. Front Oncol. 2022;12:851877.","journal-title":"Front Oncol"},{"issue":"1","key":"401_CR321","volume":"2019","author":"B Hou","year":"2019","unstructured":"Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers. 2019;2019(1):3425291.","journal-title":"Dis Markers"},{"key":"401_CR322","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1435127","volume":"15","author":"H Wan","year":"2024","unstructured":"Wan H, Weng S, Sheng S, Kuang Z, Wang Q, Hu L. Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis. Front Immunol. 2024;15:1435127. https:\/\/doi.org\/10.3389\/fimmu.2024.1435127.","journal-title":"Front Immunol"},{"key":"401_CR323","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1478888","volume":"14","author":"J Liu","year":"2025","unstructured":"Liu J, An Y, Sun R, Zhang X, Guo S, Gao X, et al. The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis. Front Oncol. 2025;14:1478888.","journal-title":"Front Oncol"},{"key":"401_CR324","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.544754","volume":"11","author":"X Xiang","year":"2020","unstructured":"Xiang X, He Q, Ou Y, Wang W, Wu Y. Efficacy and safety of CAR-modified T cell therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis of prospective clinical trials. Front Pharmacol. 2020;11:544754.","journal-title":"Front Pharmacol"},{"issue":"1","key":"401_CR325","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cancers11010047","volume":"11","author":"WL Yu","year":"2019","unstructured":"Yu WL, Hua ZC. Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: efficacy and safety\u2014a systematic review with meta-analysis. Cancers. 2019;11(1):47.","journal-title":"Cancers"},{"issue":"1","key":"401_CR326","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-019-0226-9","volume":"8","author":"S Daniel","year":"2019","unstructured":"Daniel S, Sullivan K, Labadie K, Pillarisetty V. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Clin Transl Med. 2019;8(1):10.","journal-title":"Clin Transl Med"},{"issue":"1","key":"401_CR327","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev-med-060619-022830","volume":"73","author":"P Jayaprakash","year":"2022","unstructured":"Jayaprakash P, Vignali PDA, Delgoffe GM, Curran MA. Hypoxia reduction sensitizes refractory cancers to immunotherapy. Annu Rev Med. 2022;73(1):251\u201365.","journal-title":"Annu Rev Med"},{"issue":"2","key":"401_CR328","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/btm2.10097","volume":"3","author":"AJ Hou","year":"2018","unstructured":"Hou AJ, Chang ZL, Lorenzini MH, Zah E, Chen YY. TGF-\u03b2\u2013responsive CAR-T cells promote anti-tumor immune function. Bioeng Transl Med. 2018;3(2):75\u201386.","journal-title":"Bioeng Transl Med"},{"key":"401_CR329","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41416-025-02977-8","volume":"132","author":"F Strassheimer","year":"2025","unstructured":"Strassheimer F, Elleringmann P, Ludmirski G, Roller B, Macas J, Alekseeva T, et al. CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma. Br J Cancer. 2025;132:849\u201360. https:\/\/doi.org\/10.1038\/s41416-025-02977-8.","journal-title":"Br J Cancer"},{"key":"401_CR330","doi-asserted-by":"publisher","unstructured":"Zhang C, Burger M, Jennewein L, Genssler S, Sch\u00f6nfeld K, Zeiner P, et al. ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. J Natl Cancer Inst. 2016;108(5). https:\/\/doi.org\/10.1093\/jnci\/djv375.","DOI":"10.1093\/jnci\/djv375"},{"key":"401_CR331","doi-asserted-by":"publisher","unstructured":"Reiss KA, Angelos MG, Dees EC, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171\u201382. https:\/\/doi.org\/10.1038\/s41591-025-03495-z.","DOI":"10.1038\/s41591-025-03495-z"},{"key":"401_CR332","doi-asserted-by":"crossref","unstructured":"Bauml J, Grover NS, Ronczka A, Cushing D, Klichinsky M, Barton D, et al. A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. Wolters Kluwer Health; 2021.","DOI":"10.1016\/S1465324921004205"},{"issue":"6","key":"401_CR333","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-023-00768-9","volume":"20","author":"D Killock","year":"2023","unstructured":"Killock D. CAR T cells induce durable remission of neuroblastoma. Nat Rev Clin Oncol. 2023;20(6):354.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8046","key":"401_CR334","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2025;637(8046):708\u201315.","journal-title":"Nature"},{"key":"401_CR335","doi-asserted-by":"publisher","first-page":"1546172","DOI":"10.3389\/fimmu.2025.1546172","volume":"16","author":"S G\u00f3mez-Melero","year":"2025","unstructured":"G\u00f3mez-Melero S, Hassouneh F, Vallejo-Berm\u00fadez IM, Ag\u00fcera-Morales E, Solana R, Caballero-Villarraso J. Tandem CAR-T cell therapy: recent advances and current challenges. Front Immunol. 2025;16:1546172.","journal-title":"Front Immunol"},{"issue":"8","key":"401_CR336","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO-24-02081","volume":"43","author":"S Ouladan","year":"2025","unstructured":"Ouladan S, Orouji E. Chimeric antigen receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy. J Clin Oncol. 2025;43(8):994\u20131005.","journal-title":"J Clin Oncol"},{"issue":"1","key":"401_CR337","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-21-0247","volume":"10","author":"LE Milling","year":"2022","unstructured":"Milling LE, Garafola D, Agarwal Y, Wu S, Thomas A, Donahue N, et al. Neoadjuvant STING activation, extended half-life IL2, and checkpoint blockade promote metastasis clearance via sustained NK-cell activation. Cancer Immunol Res. 2022;10(1):26\u201339.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"401_CR338","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200844","volume":"218","author":"N Xu","year":"2020","unstructured":"Xu N, Palmer DC, Robeson AC, Shou P, Bommiasamy H, Laurie SJ, et al. Sting agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2020;218(2):e20200844.","journal-title":"J Exp Med"},{"issue":"12","key":"401_CR339","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","volume":"38","author":"T Lei","year":"2024","unstructured":"Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024;38(12):2517\u201343.","journal-title":"Leukemia"},{"key":"401_CR340","doi-asserted-by":"publisher","first-page":"1063454","DOI":"10.3389\/fimmu.2023.1063454","volume":"14","author":"Y Kong","year":"2023","unstructured":"Kong Y, Tang L, You Y, Li Q, Zhu X. Analysis of causes for poor persistence of CAR-T cell therapy in vivo. Front Immunol. 2023;14:1063454.","journal-title":"Front Immunol"},{"issue":"1","key":"401_CR341","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40364-024-00602-z","volume":"12","author":"P Song","year":"2024","unstructured":"Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo D. CRISPR\/Cas-based CAR-T cells: production and application. Biomark Res. 2024;12(1):54.","journal-title":"Biomark Res"},{"issue":"6","key":"401_CR342","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.ymthe.2025.01.035","volume":"33","author":"M Khalifeh","year":"2025","unstructured":"Khalifeh M, Salman H. Engineering resilient CAR T cells for immunosuppressive environment. Mol Ther. 2025;33(6):2391\u2013405.","journal-title":"Mol Ther"},{"issue":"1","key":"401_CR343","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):10541.","journal-title":"Sci Rep"},{"key":"401_CR344","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252. https:\/\/doi.org\/10.1016\/j.biopha.2024.117252.","journal-title":"Biomed Pharmacother"},{"key":"401_CR345","doi-asserted-by":"publisher","unstructured":"Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, et al. T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther. 2022;7. https:\/\/doi.org\/10.1038\/s41392-022-00898-z.","DOI":"10.1038\/s41392-022-00898-z"},{"key":"401_CR346","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e0 G, et al. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2:904\u201318. https:\/\/doi.org\/10.1038\/s43018-021-00244-2.","journal-title":"Nat Cancer"},{"issue":"2","key":"401_CR347","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.bcd-20-0020","volume":"1","author":"F De Larrea","year":"2020","unstructured":"De Larrea F, Staehr M, Lopez A, Ng K, Chen Y, Godfrey W, et al. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood Cancer Discov. 2020;1(2):146\u201354. https:\/\/doi.org\/10.1158\/2643-3230.bcd-20-0020.","journal-title":"Blood Cancer Discov"},{"key":"401_CR348","doi-asserted-by":"publisher","unstructured":"Liu Q, Li JY, Zheng H, Yang S, Hua Y, Huang N, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22. https:\/\/doi.org\/10.1186\/s12943-023-01735-9.","DOI":"10.1186\/s12943-023-01735-9"},{"issue":"10","key":"401_CR349","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.cd-18-0442","volume":"8","author":"R Majzner","year":"2018","unstructured":"Majzner R, Mackall C. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-0442.","journal-title":"Cancer Discov"},{"key":"401_CR350","doi-asserted-by":"publisher","unstructured":"Kailayangiri S, Altvater B, Wiebel M, Jamitzky S, Rossig C. Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. Cancers. 2020;12. https:\/\/doi.org\/10.3390\/cancers12051075.","DOI":"10.3390\/cancers12051075"},{"key":"401_CR351","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015184","author":"F Cichocki","year":"2022","unstructured":"Cichocki F, Goodridge J, Bjordahl R, Mahmood S, Davis Z, Gaidarova S, et al. Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood. 2022. https:\/\/doi.org\/10.1182\/blood.2021015184.","journal-title":"Blood"},{"issue":"10","key":"401_CR352","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0.","journal-title":"Cell Mol Immunol"},{"key":"401_CR353","doi-asserted-by":"publisher","unstructured":"Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13. https:\/\/doi.org\/10.1186\/s13045-020-00890-6.","DOI":"10.1186\/s13045-020-00890-6"},{"key":"401_CR354","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen Y, Yu Z, Tan X, Jiang HF, Xu Z, Fang Y, et al. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605. https:\/\/doi.org\/10.1016\/j.biopha.2021.111605.","journal-title":"Biomed Pharmacother"},{"key":"401_CR355","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Garc\u00eda A, Lynn R, Poussin M, Eiva M, Shaw L, O\u2019Connor R, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12. https:\/\/doi.org\/10.1038\/s41467-021-20893-2.","DOI":"10.1038\/s41467-021-20893-2"},{"key":"401_CR356","doi-asserted-by":"publisher","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.783305.","DOI":"10.3389\/fimmu.2021.783305"},{"key":"401_CR357","doi-asserted-by":"publisher","unstructured":"Liu M, Liu J, Liang Z, Dai K, Gan JL, Wang Q, et al. CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro. Cells. 2022;11. https:\/\/doi.org\/10.3390\/cells11223692.","DOI":"10.3390\/cells11223692"},{"key":"401_CR358","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-6104","author":"P Watchmaker","year":"2025","unstructured":"Watchmaker P, Hatae R, Yamamichi A, Kyewalabye K, Okada K, Phyu S, et al. Abstract 6104: Comparative evaluation of CAR-expressing T-, NK-, NKT-cells and macrophages in an immunocompetent mouse glioma model. Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1538-7445.am2025-6104.","journal-title":"Cancer Res"},{"key":"401_CR359","doi-asserted-by":"publisher","unstructured":"Hatae R, Watchmaker P, Yamamichi A, Kyewalabye K, Okada K, Phyu S, et al. Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model. Neuro Oncol Adv. 2025;7. https:\/\/doi.org\/10.1093\/noajnl\/vdaf074.","DOI":"10.1093\/noajnl\/vdaf074"},{"key":"401_CR360","doi-asserted-by":"publisher","unstructured":"Guo JH, Afzal A, Ahmad S, Saeed G, Rehman A, Saddozai U, et al. Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1550652.","DOI":"10.3389\/fimmu.2025.1550652"},{"key":"401_CR361","doi-asserted-by":"publisher","unstructured":"Li J, Hu H, Lian K, Zhang D, Hu P, He Z, et al. CAR-NK cells in combination therapy against cancer: a potential paradigm. Heliyon. 2024;10. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27196.","DOI":"10.1016\/j.heliyon.2024.e27196"},{"issue":"4","key":"401_CR362","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/1566523222666211217091724","volume":"22","author":"O Cienfuegos-Jimenez","year":"2022","unstructured":"Cienfuegos-Jimenez O, Vazquez-Garza E, Rojas-Martinez A. CAR-NK cells for cancer therapy: molecular redesign of the innate antineoplastic response. Curr Gene Ther. 2022;22(4):303\u201318.","journal-title":"Curr Gene Ther"},{"issue":"6","key":"401_CR363","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061382","volume":"9","author":"IM Montagner","year":"2020","unstructured":"Montagner IM, Penna A, Fracasso G, Carpanese D, Dalla Piet\u00e0 A, Barbieri V, et al. Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer. Cells. 2020;9(6):1382.","journal-title":"Cells"},{"key":"401_CR364","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1447147","volume":"11","author":"J Vukovic","year":"2024","unstructured":"Vukovic J, Abazovic D, Vucetic D, Medenica S. CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases. Front Med. 2024;11:1447147.","journal-title":"Front Med"},{"issue":"7","key":"401_CR365","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102515","volume":"20","author":"Y Fang","year":"2025","unstructured":"Fang Y, Chen Y, Li YR. Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform. Stem Cell Reports. 2025;20(7):102515. https:\/\/doi.org\/10.1016\/j.stemcr.2025.102515.","journal-title":"Stem Cell Reports"},{"issue":"8","key":"401_CR366","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR t-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"issue":"10","key":"401_CR367","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Luckensen","year":"2022","unstructured":"Luckensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"issue":"6","key":"401_CR368","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Wirsching A, Hagen M, V\u00f6lkl S, Tur C, Raimondo MG, et al. BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med. 2025;31(6):1793\u20137. https:\/\/doi.org\/10.1038\/s41591-025-03718-3.","journal-title":"Nat Med"},{"issue":"2","key":"401_CR369","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","volume":"80","author":"B Zhang","year":"2021","unstructured":"Zhang B, Wang Y, Yuan Y, Sun J, Liu L, Huang D, et al. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Ann Rheum Dis. 2021;80(2):176\u201384. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217844.","journal-title":"Ann Rheum Dis"},{"key":"401_CR370","unstructured":"Therapeutics K. Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS. Press Release. September 24, 2025."},{"issue":"10","key":"401_CR371","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100749","volume":"6","author":"D Wang","year":"2025","unstructured":"Wang D, Wang X, Tan B, Wen X, Ye S, Wu Y, et al. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med. 2025;6(10):100749. https:\/\/doi.org\/10.1016\/j.medj.2025.100749.","journal-title":"Med"},{"issue":"12","key":"401_CR372","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/jci138416","volume":"130","author":"J Lee","year":"2020","unstructured":"Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF, et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest. 2020;130(12):6317\u201324. https:\/\/doi.org\/10.1172\/jci138416.","journal-title":"J Clin Invest"},{"issue":"9","key":"401_CR373","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1172\/jci57379","volume":"121","author":"H Takahashi","year":"2011","unstructured":"Takahashi H, Kouno M, Nagao K, Wada N, Hata T, Nishimoto S, et al. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J Clin Invest. 2011;121(9):3677\u201388. https:\/\/doi.org\/10.1172\/jci57379.","journal-title":"J Clin Invest"},{"key":"401_CR374","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","volume":"9","author":"M Fransson","year":"2012","unstructured":"Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, et al. CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation. 2012;9:112. https:\/\/doi.org\/10.1186\/1742-2094-9-112.","journal-title":"J Neuroinflammation"},{"key":"401_CR375","doi-asserted-by":"publisher","unstructured":"M\u0171zes G, Sipos F. CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option. Cells. 2023;12(11). https:\/\/doi.org\/10.3390\/cells12111534.","DOI":"10.3390\/cells12111534"},{"issue":"1","key":"401_CR376","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","volume":"21","author":"J Frikeche","year":"2024","unstructured":"Frikeche J, David M, Mouska X, Treguer D, Cui Y, Rouquier S, et al. MOG-specific CAR Tregs reverse EAE in mice. J Neuroinflammation. 2024;21(1):268. https:\/\/doi.org\/10.1186\/s12974-024-03262-w.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"401_CR377","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/eji.200838427","volume":"39","author":"Z Jiang","year":"2009","unstructured":"Jiang Z, Li H, Fitzgerald DC, Zhang GX, Rostami MA. MOG(35\u201355) i.v suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK\/STAT pathways. Eur J Immunol. 2009;39(3):789\u201399. https:\/\/doi.org\/10.1002\/eji.200838427.","journal-title":"Eur J Immunol"},{"issue":"12","key":"401_CR378","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, et al. Research priorities for an HIV cure: International AIDS Society global scientific strategy 2021. Nat Med. 2021;27(12):2085\u201398. https:\/\/doi.org\/10.1038\/s41591-021-01590-5.","journal-title":"Nat Med"},{"key":"401_CR379","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14080774","author":"M Kourti","year":"2025","unstructured":"Kourti M, Evangelidis P, Roilides E, Iosifidis E. Chimeric antigen receptor immunotherapy for infectious diseases: current advances and future perspectives. Pathogens. 2025. https:\/\/doi.org\/10.3390\/pathogens14080774.","journal-title":"Pathogens"},{"key":"401_CR380","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","volume":"18","author":"C Slabik","year":"2020","unstructured":"Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, et al. CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther. 2020;18:504\u201324. https:\/\/doi.org\/10.1016\/j.omto.2020.08.005.","journal-title":"Mol Ther"},{"key":"401_CR381","doi-asserted-by":"publisher","unstructured":"Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci Transl Med. 2019;11(504). https:\/\/doi.org\/10.1126\/scitranslmed.aav5685.","DOI":"10.1126\/scitranslmed.aav5685"},{"issue":"2","key":"401_CR382","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2022.281719","volume":"108","author":"G Chen","year":"2022","unstructured":"Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K, et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2022;108(2):615.","journal-title":"Haematologica"},{"issue":"3","key":"401_CR383","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","volume":"13","author":"N Jakharia","year":"2021","unstructured":"Jakharia N, Howard D, Riedel DJ. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies. Curr Treat Options Infect Dis. 2021;13(3):123\u201340.","journal-title":"Curr Treat Options Infect Dis"},{"issue":"6","key":"401_CR384","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1158\/2767-9764.crc-23-0538","volume":"4","author":"SP Yeo","year":"2024","unstructured":"Yeo SP, Kua L, Tan JW, Lim JK, Wong FH, Santos MD, et al. B7\u2013H3-targeting chimeric antigen receptors Epstein-Barr virus-specific T cells provides a tumor agnostic off-the-shelf therapy against B7\u2013H3-positive solid tumors. Cancer Res Commun. 2024;4(6):1410\u201329. https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0538.","journal-title":"Cancer Res Commun"},{"issue":"5","key":"401_CR385","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","volume":"20","author":"RL Kruse","year":"2018","unstructured":"Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. 2018;20(5):697\u2013705. https:\/\/doi.org\/10.1016\/j.jcyt.2018.02.002.","journal-title":"Cytotherapy"},{"issue":"664","key":"401_CR386","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1209","volume":"14","author":"M Seif","year":"2022","unstructured":"Seif M, Kakoschke TK, Ebel F, Bellet MM, Trinks N, Renga G, et al. CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Sci Transl Med. 2022;14(664):eabh1209. https:\/\/doi.org\/10.1126\/scitranslmed.abh1209.","journal-title":"Sci Transl Med"},{"issue":"29","key":"401_CR387","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.1312789111","volume":"111","author":"PR Kumaresan","year":"2014","unstructured":"Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA. 2014;111(29):10660\u20135. https:\/\/doi.org\/10.1073\/pnas.1312789111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"401_CR388","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1016\/j.cell.2023.08.044","volume":"186","author":"F Wimmers","year":"2023","unstructured":"Wimmers F, Burrell AR, Feng Y, Zheng H, Arunachalam PS, Hu M, et al. Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth. Cell. 2023;186(21):4632-51.e23. https:\/\/doi.org\/10.1016\/j.cell.2023.08.044.","journal-title":"Cell"},{"issue":"2","key":"401_CR389","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jcyt.2020.11.002","volume":"23","author":"TA da Silva","year":"2021","unstructured":"da Silva TA, Hauser PJ, Bandey I, Laskowski T, Wang Q, Najjar AM, et al. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy. Cytotherapy. 2021;23(2):119\u201330. https:\/\/doi.org\/10.1016\/j.jcyt.2020.11.002.","journal-title":"Cytotherapy"},{"issue":"1","key":"401_CR390","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2023.2281059","volume":"14","author":"MP Machado","year":"2023","unstructured":"Machado MP, Dos Santos MH, Guimar\u00e3es JG, de Campos GY, Oliveira Brito PKM, Ferreira CMG, et al. GXMR-CAR containing distinct GXM-specific single-chain variable fragment (scFv) mediated the cell activation against Cryptococcus spp. and had difference in the strength of tonic signaling. Bioengineered. 2023;14(1):2281059. https:\/\/doi.org\/10.1080\/21655979.2023.2281059.","journal-title":"Bioengineered"},{"issue":"1","key":"401_CR391","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"401_CR392","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imr.12772","volume":"290","author":"SS Chandran","year":"2019","unstructured":"Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev. 2019;290(1):127\u201347. https:\/\/doi.org\/10.1111\/imr.12772.","journal-title":"Immunol Rev"},{"key":"401_CR393","doi-asserted-by":"crossref","unstructured":"Cao LY, Zhao Y, Chen Y, Ma P, Xie JC, Pan XM, et al. CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials. gov insights. Front Immunol. 2025;16:1583116.","DOI":"10.3389\/fimmu.2025.1583116"},{"key":"401_CR394","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik J, Hancock A, Leibowitz M, Li L, et al. Targeting Cardiac Fibrosis with Engineered T cells. Nature. 2019;573:430\u20133. https:\/\/doi.org\/10.1038\/s41586-019-1546-z.","journal-title":"Nature"},{"key":"401_CR395","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114760","volume":"157","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Li H, Jiang Y, Yang P, Yin G, Yang L, et al. Fibroblast activation protein-targeted chimeric antigen-receptor-modified NK cells reverse cardiac fibrosis. Int Immunopharmacol. 2025;157:114760. https:\/\/doi.org\/10.1016\/j.intimp.2025.114760.","journal-title":"Int Immunopharmacol"},{"key":"401_CR396","doi-asserted-by":"publisher","unstructured":"Zhang Q, Dai J, Liu T, Rao W, Li D, Gu Z, et al. Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells. Mol Cell Biochem. 2024. https:\/\/doi.org\/10.1007\/s11010-024-05134-6.","DOI":"10.1007\/s11010-024-05134-6"},{"key":"401_CR397","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"J Rurik","year":"2022","unstructured":"Rurik J, Tomb\u00e1cz I, Yadegari A, Fern\u00e1ndez PM, Shewale S, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"key":"401_CR398","doi-asserted-by":"publisher","unstructured":"Jiang YH, Zhou M, Cheng MD, Chen S, Guo Y. CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS. JCI Insight. 2025;10. https:\/\/doi.org\/10.1172\/jci.insight.182050.","DOI":"10.1172\/jci.insight.182050"},{"key":"401_CR399","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10741-022-10279-x","volume":"28","author":"P Morfino","year":"2022","unstructured":"Morfino P, Aimo A, Castiglione V, G\u00e1lvez-Mont\u00f3n C, Emdin M, Bay\u00e9s-Gen\u00eds A. Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy. Heart Fail Rev. 2022;28:555\u201369. https:\/\/doi.org\/10.1007\/s10741-022-10279-x.","journal-title":"Heart Fail Rev"},{"key":"401_CR400","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.034","author":"H Dai","year":"2024","unstructured":"Dai H, Zhu C, Huai Q, Xu W, Zhu J, Zhang X, et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.034.","journal-title":"J Hepatol"},{"key":"401_CR401","doi-asserted-by":"publisher","unstructured":"Yan J, Wang SY, Su Q, Zou MW, Zhou ZY, Shou J, et al. Targeted immunotherapy rescues pulmonary fibrosis by removing activated fibroblasts. Nat Commun. 2025;16. https:\/\/doi.org\/10.1038\/s41467-025-59093-7.","DOI":"10.1038\/s41467-025-59093-7"},{"key":"401_CR402","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114061","volume":"158","author":"G Ferrer-Curriu","year":"2022","unstructured":"Ferrer-Curriu G, Soler-Botija C, Charv\u00e1tov\u00e1 S, Motais B, Roura S, G\u00e1lvez-Mont\u00f3n C, et al. Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy. Biomed Pharmacother. 2022;158:114061. https:\/\/doi.org\/10.1016\/j.biopha.2022.114061.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"401_CR403","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1111\/cas.16285","volume":"115","author":"S Meng","year":"2024","unstructured":"Meng S, Hara T, Miura Y, Ishii H. Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors. Cancer Sci. 2024;115(11):3532\u201342.","journal-title":"Cancer Sci"},{"key":"401_CR404","doi-asserted-by":"publisher","unstructured":"Sueangoen N, Prasongtanakij S. Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer. Clin Exp Med. 2025;25. https:\/\/doi.org\/10.1007\/s10238-025-01820-x.","DOI":"10.1007\/s10238-025-01820-x"},{"key":"401_CR405","doi-asserted-by":"publisher","unstructured":"Wang W, Hu K, Xue J, Chen J, Du X, Zhao T, et al. In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier. J Control Release. 2025:113888. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113888.","DOI":"10.1016\/j.jconrel.2025.113888"},{"key":"401_CR406","doi-asserted-by":"publisher","unstructured":"Shin M, Oh E, Kim Y, Nam D, Jeon SY, Yu J, et al. Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells. 2023;12. https:\/\/doi.org\/10.3390\/cells14121606.","DOI":"10.3390\/cells14121606"},{"key":"401_CR407","doi-asserted-by":"publisher","unstructured":"Deng Y, Kumar A, Xie K, Schaaf K, Scifo E, Morsy S, et al. Targeting senescent cells with NKG2D-CAR T cells. Cell Death Discov. 2024;10. https:\/\/doi.org\/10.1038\/s41420-024-01976-7.","DOI":"10.1038\/s41420-024-01976-7"},{"key":"401_CR408","doi-asserted-by":"publisher","unstructured":"Khalil R, Diab\u2010Assaf M, Lema\u00eetre J. Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies. Cells. 2023;12. https:\/\/doi.org\/10.3390\/cells12060915.","DOI":"10.3390\/cells12060915"},{"issue":"7","key":"401_CR409","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.tibs.2020.03.008","volume":"45","author":"S Song","year":"2020","unstructured":"Song S, Lam E, Tchkonia T, Kirkland J, Sun Y. Senescent cells: emerging targets for human aging and age-related diseases. Trends Biochem Sci. 2020;45(7):578\u201392. https:\/\/doi.org\/10.1016\/j.tibs.2020.03.008.","journal-title":"Trends Biochem Sci"},{"key":"401_CR410","doi-asserted-by":"publisher","unstructured":"Yang D, Sun B, Li S, Wei W, Liu X, Cui X, et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci Transl Med. 2023;15. https:\/\/doi.org\/10.1126\/scitranslmed.add1951.","DOI":"10.1126\/scitranslmed.add1951"},{"key":"401_CR411","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","volume":"4","author":"C Amor","year":"2024","unstructured":"Amor C, Fern\u00e1ndez-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging. 2024;4:336\u201349. https:\/\/doi.org\/10.1038\/s43587-023-00560-5.","journal-title":"Nat Aging"},{"key":"401_CR412","doi-asserted-by":"publisher","unstructured":"Amor C, Fern\u00e1ndez-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Research Square. 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-3385749\/v1.","DOI":"10.21203\/rs.3.rs-3385749\/v1"},{"issue":"15","key":"401_CR413","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.182050","volume":"10","author":"YH Jiang","year":"2025","unstructured":"Jiang YH, Zhou M, Cheng MD, Chen S, Guo Y. CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS. JCI Insight. 2025;10(15):e182050.","journal-title":"JCI Insight"},{"issue":"2","key":"401_CR414","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.stem.2020.07.010","volume":"27","author":"J Li","year":"2020","unstructured":"Li J, Chen Y. A fresh approach to targeting aging cells: CAR-T cells enhance senolytic specificity. Cell Stem Cell. 2020;27(2):192\u20134. https:\/\/doi.org\/10.1016\/j.stem.2020.07.010.","journal-title":"Cell Stem Cell"},{"key":"401_CR415","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.08.011","author":"J Feucht","year":"2020","unstructured":"Feucht J, Abou-El-Enein M. Senolytic CAR T cells in solid tumors and age-related pathologies. Mol Ther. 2020. https:\/\/doi.org\/10.1016\/j.ymthe.2020.08.011.","journal-title":"Mol Ther"},{"issue":"22","key":"401_CR416","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1182\/bloodadvances.2019000411","volume":"3","author":"S B\u00e9zie","year":"2019","unstructured":"B\u00e9zie S, Charreau B, Vimond N, Lasselin J, G\u00e9rard N, N\u00e9rri\u00e8re-Daguin V, et al. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice. Blood Adv. 2019;3(22):3522\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2019000411.","journal-title":"Blood Adv"},{"key":"401_CR417","doi-asserted-by":"publisher","unstructured":"Cassano A, Chong A, Alegre M. Tregs in transplantation tolerance: role and therapeutic potential. Front Transplant. 2023;2. https:\/\/doi.org\/10.3389\/frtra.2023.1217065.","DOI":"10.3389\/frtra.2023.1217065"},{"key":"401_CR418","doi-asserted-by":"publisher","unstructured":"Rosado-S\u00e1nchez I, Haque M, Salim K, Speck M, Fung V, Boardman D, et al. Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection. JCI Insight. 2023;8. https:\/\/doi.org\/10.1172\/jci.insight.167215.","DOI":"10.1172\/jci.insight.167215"},{"key":"401_CR419","doi-asserted-by":"publisher","unstructured":"Zhang Q, Lu W, Liang CL, Chen Y, Liu H, Qiu F, et al. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance. Front Immunol. 2018;9. https:\/\/doi.org\/10.3389\/fimmu.2018.02359.","DOI":"10.3389\/fimmu.2018.02359"},{"key":"401_CR420","doi-asserted-by":"publisher","unstructured":"Muller Y, Ferreira L, Ronin E, Ho P, Nguyen V, Faleo G, et al. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.686439.","DOI":"10.3389\/fimmu.2021.686439"},{"key":"401_CR421","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.212.supp.1545.5087","author":"S Durgam","year":"2024","unstructured":"Durgam S, Sayin I, Hynes G, Yin D, Sanchez IR, Speck M, et al. HLA-A2 chimeric antigen receptor regulatory T cells promote allograft acceptance in mice. J Immunol. 2024. https:\/\/doi.org\/10.4049\/jimmunol.212.supp.1545.5087.","journal-title":"J Immunol"},{"key":"401_CR422","doi-asserted-by":"publisher","unstructured":"Ni X, Wang Q, Gu J, Lu L. Clinical and Basic Research Progress on Treg-Induced Immune Tolerance in Liver Transplantation. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.535012.","DOI":"10.3389\/fimmu.2021.535012"},{"key":"401_CR423","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.10.002","author":"A Martin","year":"2020","unstructured":"Martin A, Daris M, Johnston J, Cui J. HLA-A*02:01-directed chimeric antigen receptor\/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease. Cytotherapy. 2020. https:\/\/doi.org\/10.1016\/j.jcyt.2020.10.002.","journal-title":"Cytotherapy"},{"issue":"19","key":"401_CR424","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310318","volume":"36","author":"J Zhang","year":"2024","unstructured":"Zhang J, Gu J, Wang X, Ji C, Yu D, Wang M, et al. Engineering and targeting neutrophils for cancer therapy. Adv Mater. 2024;36(19):2310318.","journal-title":"Adv Mater"},{"issue":"2","key":"401_CR425","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007329","volume":"12","author":"SN Shishido","year":"2024","unstructured":"Shishido SN, Hart O, Jeong S, Moriarty A, Heeke D, Rossi J, et al. Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy. J Immunother Cancer. 2024;12(2):e007329.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"401_CR426","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202414368","volume":"35","author":"H Chen","year":"2025","unstructured":"Chen H, Machado A, An D, Becharef S, Autret G, Ayollo D, et al. In vivo monitoring and magnetically-enhanced delivery of CAR T-cells to solid tumor. Adv Funct Mater. 2025;35(5):2414368.","journal-title":"Adv Funct Mater"},{"issue":"7","key":"401_CR427","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/15353702221074293","volume":"247","author":"T Head","year":"2022","unstructured":"Head T, Cady NC. Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling. Exp Biol Med. 2022;247(7):598\u2013613.","journal-title":"Exp Biol Med"},{"issue":"10","key":"401_CR428","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1089\/hum.2012.202","volume":"24","author":"SN De Oliveira","year":"2013","unstructured":"De Oliveira SN, Ryan C, Giannoni F, Hardee CL, Tremcinska I, Katebian B, et al. Modification of hematopoietic stem\/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum Gene Ther. 2013;24(10):824\u201339.","journal-title":"Hum Gene Ther"},{"key":"401_CR429","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129746","volume":"134","author":"HY Liu","year":"2019","unstructured":"Liu HY, Rahman N, Chiou TT, De Oliveira SN. Dissecting the immune cell progeny of CAR-expressing hematopoietic stem cells in a humanized mouse model. Blood. 2019;134:4640.","journal-title":"Blood"},{"issue":"8","key":"401_CR430","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002866","volume":"9","author":"M Bachiller","year":"2021","unstructured":"Bachiller M, Perez-Amill L, Battram AM, Carn\u00e9 SC, Najjar A, Verhoeyen E, et al. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness. J Immunother Cancer. 2021;9(8):e002866.","journal-title":"J Immunother Cancer"},{"key":"401_CR431","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1432799","volume":"15","author":"A Ali","year":"2024","unstructured":"Ali A, DiPersio JF. Recarving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. Front Immunol. 2024;15:1432799.","journal-title":"Front Immunol"},{"key":"401_CR432","doi-asserted-by":"publisher","unstructured":"Sainatham C, Yadav D, Babu D, Tallapalli J, Kanagala S, Filippov E, et al. The current socioeconomic and regulatory landscape of immune effector cell therapies. Front Med. 2024;11. https:\/\/doi.org\/10.3389\/fmed.2024.1462307.","DOI":"10.3389\/fmed.2024.1462307"},{"key":"401_CR433","doi-asserted-by":"publisher","unstructured":"Pang Z, Wang Z, Li F, Feng C, Mu X. Current Progress of CAR-NK Therapy in Cancer Treatment. Cancers. 2022;14. https:\/\/doi.org\/10.3390\/cancers14174318.","DOI":"10.3390\/cancers14174318"},{"key":"401_CR434","doi-asserted-by":"publisher","unstructured":"Pfefferle A, Huntington N. You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. Cancers. 2020;12. https:\/\/doi.org\/10.3390\/cancers12030706.","DOI":"10.3390\/cancers12030706"},{"key":"401_CR435","doi-asserted-by":"publisher","unstructured":"Devi K, Joga R, Srivastava S, Nagpal K, Dhamija I, Grover P, et al. Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India. Eur J Pharm Biopharm. 2024:114361. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114361.","DOI":"10.1016\/j.ejpb.2024.114361"},{"key":"401_CR436","doi-asserted-by":"publisher","unstructured":"Zhao X, Xiong J, Li D, Zhang Y. Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review. Front Med. 2025. https:\/\/doi.org\/10.3389\/fmed.2025.1655693.","DOI":"10.3389\/fmed.2025.1655693"},{"issue":"1","key":"401_CR437","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12935-023-03022-5","volume":"23","author":"M Eslami","year":"2023","unstructured":"Eslami M, Khazeni S, Khanaghah XM, Asadi MH, Ansari MA, Garjan JH, et al. Mirna-related metastasis in oral cancer: moving and shaking. Cancer Cell Int. 2023;23(1):182.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"401_CR438","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10142-025-01612-2","volume":"25","author":"M Hashemi","year":"2025","unstructured":"Hashemi M, Khanaghah XM, Nahand JS. The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy. Funct Integr Genomics. 2025;25(1):113.","journal-title":"Funct Integr Genomics"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00401-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00401-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00401-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:44:30Z","timestamp":1768970670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00401-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":438,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00401-4","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}